 
 
 Protocol I8F-MC-GPIL 
 
An Open-Label, Single-Arm, Phase 4 Study to Assess Glycemic Control When Adults with Type 2 
Diabetes Switch from a GLP-1 RA to Tirzepatide (SURPASS-SWITCH-2)  
 
 
[STUDY_ID_REMOVED] 
 
 
Approval Date: 26-Aug-2022 
 
 
   
 
CONFIDENTIAL I8F-MC-GPIL 
1  Title Page 
Confidential Information 
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the pro perty of 
Eli Lilly and Company or its subsidiaries and should not be copi[INVESTIGATOR_291569]  (LY3298176), unless such persons are bound by a confidentiality agreement with Eli Lilly and Company 
or its subsidiaries.  
 
Note to Regulatory Authorities:  This document may contain protected personal data and/or commercially confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/red action prior to any public rele ase. 
In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries 
Protocol Title: An Open-Label, Single-Arm, Phase 4 Study to Assess Glycemic Control When 
Adults with Type 2 Diabetes Switch from a GLP-1 RA to Tirzepatide (SURPASS-SWITCH-2) 
Protocol Number: I8F-MC-GPIL 
Amendment Number: This is the initial protocol.  
Compound: LY3298176  
Brief Title: A study to  investigate glycemic control in adults  with type 2 diabetes switching to 
tirzepatide from a GLP-1 RA  
Study Phase: 4 
Acronym:  SURPASS-SWITCH-2 
Sponsor Name:  [CONTACT_11028]: Indianapolis, Indiana, [LOCATION_003] [ZIP_CODE]  
Regulatory Agency Identifier Number(s) 
IND: [ADDRESS_355799]: 2022-002708-18 
Approval Date: Protocol Electronically Signed and Approved by [CONTACT_81098]. 
Document ID: VV-CLIN-067244  
$SSURYHGRQ$XJ*[ADDRESS_355800] Inform ation will be provided separately. 
  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
3 Table of Contents 
1. Protocol Summary ..........................................................................................................6  
1.1. Synopsis ...................................................................................................................... ......6  
1.2. Schema ........................................................................................................................ ....11  
1.3. Schedule of Activities (SoA) ..........................................................................................12  
2. Introduction .................................................................................................................. .22 
2.1. Study Rationale ............................................................................................................... 22 
2.2. Background .................................................................................................................... .22 
2.3. Benefit/Risk Assessment ................................................................................................23  
2.3.1.  Risk Assessment .............................................................................................................23  
2.3.2.  Benefit Assessment .........................................................................................................23  
2.3.3.  Overall Benefit Risk Conclusion ....................................................................................23  
3. Objectives, Endpoints, and Estimands .......................................................................25  
4. Study Design .................................................................................................................. 27 
4.1. Overall Design ................................................................................................................ 27 
4.1.1.  Design Outline ................................................................................................................ 27 
4.2. Scientific Rationale for Study Design ............................................................................28  
4.3. Justification for Dose ......................................................................................................28  
4.4. End of Study Definition ..................................................................................................29  
5. Study Population ...........................................................................................................30  
5.1. Inclusion Criteria ............................................................................................................30  
5.2. Exclusion Criteria ...........................................................................................................31  
5.3. Lifestyle Considerations .................................................................................................33  
5.4. Screen Failures ............................................................................................................... .33 
5.5. Criteria for Temporarily Delaying Enrollment of a Participant .....................................33  
6. Study Intervention(s) and Concomitant Therapy .....................................................34  
6.1. Study Intervention(s) Administered................................................................................34  
6.1.1.  Medical Devices..............................................................................................................35  
6.1.2.  Rescue Therapy ...............................................................................................................3 5 
6.1.3.  Background Therapy .......................................................................................................35  
6.2. Preparation, Handling, Storage, and Accountability ......................................................35  
6.3. Measures to Minimize Bias: Randomization and Blinding ............................................36  
6.4. Study Intervention Compliance ......................................................................................36  
6.5. Dose Modification ..........................................................................................................36  
6.5.1.  Management of Participants with Gastrointestinal Symptoms .......................................36  
6.6. Continued Access to Study Intervention after the End of the 
Study ......................................................................................................................... ......37  
6.7. Treatment of Overdose ...................................................................................................37  
6.7.1.  Tirzepatide Overdose ......................................................................................................37  
6.8. Prior and Concomitant Therapy ......................................................................................37  
6.8.1.  Allowed Concomitant Therapy .......................................................................................37  
6.8.2.  Changing Concomitant Therapy .....................................................................................38  
6.8.3.  Concomitant Therapy Data Collection ...........................................................................38  
6.8.4.  Prohibited Concomitant Medications .............................................................................38  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
4 6.8.5.  Allowed Antihyperglycemic Treatme nts other than Tirzepatide ....................................38  
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal........................................................................................39  
7.1. Discontinuation of Study Intervention ............................................................................39  
7.1.1.  Liver Chemistry Stoppi[INVESTIGATOR_2121] ..................................................................................40  
7.1.2.  Temporary Discontinuation of Study Intervention .........................................................41  
7.2. Participant Discontinuation/Withdrawal from the Study ................................................[ADDRESS_355801] to Follow-Up ...........................................................................................................42  
8. Study Assessments and Procedures.............................................................................43  
8.1. Efficacy Assessments .....................................................................................................43  
8.1.1.  Self-Monitoring of Blood Glucose (SMBG) ..................................................................[ADDRESS_355802] ....................................................................................54  
8.4. Pharmacokinetics ............................................................................................................57  
8.5. Pharmacodynamics .........................................................................................................57  
8.6. Genetics ...................................................................................................................... ....57  
8.7. Biomarkers .................................................................................................................... ..58 
8.8. Immunogenicity Assessments.........................................................................................58  
8.9. Health Economics ...........................................................................................................58  
9. Statistical Considerations .............................................................................................59  
9.1. Statistical Hypotheses .....................................................................................................59  
9.2. Analyses Sets ..................................................................................................................59  
9.3. Statistical Analyses .........................................................................................................59  
9.3.1.  General Considerations ...................................................................................................59  
9.3.2.  Primary Endpoint Analysis .............................................................................................60  
9.3.3.  Secondary Endpoints Analysis .......................................................................................60  
9.3.4.  Exploratory Endpoints Analysis .....................................................................................60  
9.3.5.  Safety Analyses ...............................................................................................................60  
9.3.6.  Subgroup Analyses .........................................................................................................61  
9.4. Interim Analysis ..............................................................................................................62  
9.5. Sample Size Determination ............................................................................................62  
10. Supporting Documentation and Operational Considerations ..................................63  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
5 10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations ................................................................................................................ 63 
10.1.1.  Regulatory and Ethical Considerations ...........................................................................63  
10.1.2.  Financial Disclosure........................................................................................................64  
10.1.3.  Informed Consent Process ..............................................................................................64  
10.1.4.  Data Protection................................................................................................................ 64 
10.1.5.  Committees Structure......................................................................................................65  
10.1.6.  Dissemination of Clinical Study Data.............................................................................65  
10.1.7.  Data Quality Assurance ..................................................................................................65  
10.1.8.  Source Documents ..........................................................................................................67  
10.1.9.  Study and Site Start and Closure ....................................................................................67  
10.1.10.  Publication Policy ...........................................................................................................6 8 
10.1.11.  Investigator Information .................................................................................................68  
10.1.12.  Sample Retention ............................................................................................................68  
10.2.  Appendix 2: Clinical Laboratory Tests ...........................................................................69  
10.2.1.  Laboratory Samples to be Obtained at the Time of a Systemic Hypersensitivity Event ....................................................................................................71
 
10.3.  Appendix 3: Adverse Events and Serious Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-Up, and Reporting ...........................................................................................................[ADDRESS_355803] Complaints ...................................................................................75  
10.3.4.  Recording and Follow-Up of AE and/or SAE and Product 
Complaints .................................................................................................................... ..76 
10.3.5.  Reporting of SAEs ..........................................................................................................77  
10.3.6.  Regulatory Reporting Requirements ...............................................................................78  
10.4.  Appendix 4: Contraceptive and Barrier Guidance ..........................................................79  
10.4.1.  Definitions.................................................................................................................... ...79  
10.4.2.  Contraception Guidance..................................................................................................80  
10.5.  Appendix 5: Liver Safety: Suggested Actions and Follow-up 
Assessments ................................................................................................................... .84 
10.6.  Appendix 6: Medical Device Adverse Events (AEs), Adverse Device Effects (ADEs), Serious Adverse Events (SAEs) and Device Deficiencies: Definition and Procedures for Recording, Evaluating, Follow-up, and Reporting ............................................................................86
 
10.7.  Appendix 7: Standardized Protocols for the Measurement of 
Height, Weight, Waist Circumference, BMI, and Vital Signs .......................................87  
10.8.  Appendix 8: Provisions for Changes in Study Conduct During 
Exceptional Circumstances .............................................................................................89  
10.9.  Appendix 9: Abbreviations and Definitions ...................................................................93  
11. References .................................................................................................................... ..98 
 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
6 1. Protocol Summary 
1.1. Synopsis 
Protocol Title: An Open-Label, Single-Arm, Phase 4 Study to Assess Glycemic Control When 
Adults with Type 2 Diabetes Switch from a GLP-1 RA to Tirzepatide (SURPASS-SWITCH-2) 
Brief Title:  A study to  investigate glycemic control in adults  with type 2 diabetes switching to 
tirzepatide from a GLP-1 RA 
Regulatory Agency Identifier Number(s):  
IND: [ADDRESS_355804]: 2022-002708-18 
Rationale: 
No study has investigated the effects of switching  from glucagon-like peptide-[ADDRESS_355805] 
(GLP-1 RA) therapy to tirzepatide in people with type 2 diabetes (T2D). This study will inform 
providers on what to expect when switching from a GLP-1 RA to tirzepatide 5 mg but does not 
evaluate long-term efficacy, optimal dosing, or comparative improvement to other regimens. 
Prior exposure to a GLP-1 RA is associated with less frequent gastrointestinal (GI) intolerance 
when switching between GLP-[ADDRESS_355806] 12 weeks for the targeted study population. 
Objectives, Endpoints, and Estimands: 
Objectives Endpoints 
Primary  
To demonstrate that participants with T2D  switching 
from a stable dose of GLP -1 RA to tirzepatide 5 mg 
QW ha ve an improvement in HbA1c at Week 12 
compared to baseline    Change from baseline in HbA1c  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
7 Secondary  
To evaluate the changes in CGM- assessed TAR from 
baseline at Week 4 and at Week 12 Change  from baseline in  
 Percentage of time per day that CGM-derived 
values are >180 mg/dl (10 mmol/L)  
 Duration of time in minutes per day that CGM-derived values are >180 mg/dl (10 mmol/L) 
To evaluate the change in FSG from baseline  at Week 
12  Change from baseline in FSG 
To evaluate  the changes from baseline in weight at 
Week  12  Change from baseline in weight 
Abbreviations: CGM = continuous glucose monitoring; FSG = fasting serum glucose; GLP-1 RA = glucagon-like 
peptide-[ADDRESS_355807]; HbA1c = hemoglobin A1c; QW  = once-weekly; T2D = type-2 diabetes; TAR = time 
above range (>180 mg/dl or >10 mmol/L). 
The primary estimand in this study is the efficacy estimand. 
The efficacy estimand focuses on the treatment effe ct if participants continued to receive the 
study treatment without prohibited medication. This estimand will be used in publications to 
inform prescribers or physicians. 
Overall Design 
SURPASS-SWITCH-2 is an open-label, single-arm, multicenter, multinational, Phase 4 study to 
assess the changes in glycemic control when switching from a stable dose of a GLP-1 RA 
directly to tirzepatide 5 mg in participants with T2D. 
This study includes a screening peri od and a 12-week treatment period. 
Brief Summary: 
Period I: Screening 
Preparation for the switch from GLP-1 RA medication to tirzepatide 
&1.27?.<=20*=8;@255-.=.;627.=1.9*;=2,29*7=L<,>;;.7=# -[ADDRESS_355808] 3 days prior to Visi t 2 but no more than 10 days prior to Visit 2. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
8 Training for the study-supplied SMBG monitor and testing frequency recommendations will 
occur. Training for the CGM sensor and insertion device, including suggestions for successful 
device maintenance, will also occur in conjunction with the insertion of the CGM sensor for the baseline measurement session. 
Period II: Treatment period 
Visit 2 Treatment Initiation 
Participants arrive to the clinic in the fasting state. This is the general flow for Visit 2 
 Participant returns screening CGM sensor for compliance review and data upload 
 Study personnel confirm enrollment criteria 
 Study personnel complete all required visit procedures, including the collection of vital 
signs, all baseline procedures, and sample collection, and 
 Treatment initiation for el igible participants. 
Study intervention training 
Study personnel will provide appropriate training for  use of the tirzepatide SDP. The training can 
be provided using a demonstration device, if avai lable. This training will be repeated at 
subsequent visits, as needed. In addition, study personnel will provide product-<9.,2/2,J27<=;>,=287</8;><.K27/8;6*=287=8
the participants upon request, if available. 
First tirzepatide dose 
Study personnel will observe as the participant injects the first dose of tirzepatide. The remaining 
injections will occur at pa ;=2,29*7=L<186.  The date and time of the first dose of tirzepatide 
should be recorded on the CRF. Additionally, all medication doses administered at home should 
+.,*9=>;.-27,5>-270-*=.*7-=26.27=1.9*;=2,29*7=L<-2*; B*7-<>+<.:>.7=5B;.,8;-.-27  the 
CRF. 
Visit 5 (Week 12) Treatment Period or ED Visit 
&1.27?.<=20*=8;@255-.=.;627.*9*;=2,29*7=L<=;*7<2=287/;86<=>-B=;.*=6.7==8*78=1.;-2*+.= es 
treatment, including re-initiation of baseline GLP-1 RA. 
Study Population: 
In general, an individual may take part in the study if they 
 Are 18 years old or of an acceptable age to provide informed consent according to local 
regulations, whichever is older. 
 Have been diagnosed with T2D based on the World Health Organization classification or other locally applicable diagnostic standards. 
 *?.*7+,GG  6685	685=8F
F  mmol/mol) as determined by [CONTACT_23283] 1 and in the opi[INVESTIGATOR_291570]. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
9  Have been on a stable treatment dose of 1 of the listed GLP- $</8;G
687=1<9;28;=8
Visit 1: 
o liraglutide 1.2 or 1.8 mg QD 
o dulaglutide 0.75, 1.5, 3, or 4.5 mg QW, or 
o injectable semaglutide 0.5, 1, or 2 mg QW 
 No treatment with oral antihyperglycemic med ication (OAM) or on stable doses (for at 
least 3 months before Visit 1) of up to 3 OAM. The OAM may include metformin (at 
least 1000 mg/day), SGLT- 2=12*C852-27.-287.<8;N -glucosidase inhibitors. 
 *?. G  kg/m2 at Visit 1. 
 Are reliable and willing to make themselves available for the duration of the study and are willing and able to follow study procedures as required, including compliance with 
CGM sensor and insertion device. 
In general, an individual may not take part in the study if they 
 Have type 1 diabetes. 
 Have a history of chronic or acute pancreatitis any time prior to Visit 1. 
 Have a clinical history of 
o proliferative diabetic retinopathy 
o diabetic maculopathy, or 
o nonproliferative diabetic retinopathy that requires acute treatment. 
 Are at high risk for cardiovascular disease in =1.27?.<=20*=8;L<89272878;1*?. a history 
of any of these cardiovascular conditions within 60 days prior to Visit 1: 
o myocardial infarction 
o percutaneous coronary reva scularization procedure 
o carotid stenting or surgical revascularization 
o nontraumatic amputation 
o peripheral vascular procedure (e.g., stenting or surgical revascularization) 
o cerebrovascular accident (stroke), or 
o hospi[INVESTIGATOR_126042] 
 Have [LOCATION_001] Heart Association Functional Classification Class IV congestive heart 
failure. 
 Have a history of ketoacidosis or hyperosmolar state or coma. 
 Have a history of severe hypoglycemia or hypoglycemia unawareness within the 6 months prior to Visit 1. 
Number of Participants: 
The study will enroll approximately 150 participants. 
Intervention Groups and Duration: 
Participants will be administered with tirzepat ide 5 mg once-weekly by [CONTACT_291585] a single-dose pen. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
10 Ethical Considerations of Benefit/Risk: 
The safety information from the tirzepatide Phase 3 clinical studies  is similar to the known safety 
information as the GLP-1 RA therapi[INVESTIGATOR_014]. 
Participants may benefit by [CONTACT_291586] l health information, routine safety assessments, 
lifestyle management counseling, and frequent en gagement with health care providers during the 
study, which provide opportunities for coaching and support. Considering the information available from previous completed clinical studies in people, and 
the measures taken to make sure the participants in this study are safe, the potential risks from taking tirzepatide are justified by [CONTACT_291587] T2D. 
Data Monitoring Committee: No 
 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
11 1.2. Schema 
 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
12 1.3. Schedule of Activities (SoA) 
Screening 
Visit [ADDRESS_355809] 8 hours without eating, drinking  (except water), or performing any significant physical activ ity before 
the visit. 
If a participant attends a fasting visit in the non-fasting s tate, the sample should still be collected, and reschedule the fas ting laboratory 
sample collection. This will not be considered a protocol deviation. 
Study I8F-MC-GPIL Period I - 
Screening Period II  - Treatment Period Comments  
Visit Number  1 2 3 4 5 ED ED = early discontinuation  
Week Relative to Study Intervention S tart -3 0 4 8 12 I  
Visit Interval Tolerance (Days) 
+3/-7 0 Â±3 Â±3 Â±3  Flexibility is built into the screening visit to 
ensure adequate CGM session and 
appropriate timing for stoppi[INVESTIGATOR_291571]-1 RA and initiating tirzepatide at Visit 
2; see Section 4.1.[ADDRESS_355810] be signed 
before any protocol -specific tests or 
procedures are performed.  
See Section 10.1.3  for additional details. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
13 Study I8F-MC-GPIL Period I - 
Screening Period II  - Treatment Period Comments  
Visit Number  1 2 3 4 5 ED ED = early discontinuation  
Week Relative to Study Intervention S tart -3 0 4 8 12 I  
Visit Interval Tolerance (Days) 
+3/-7 0 Â±3 Â±3 Â±3  Flexibility is built into the screening visit to 
ensure adequate CGM session and 
appropriate timing for stoppi[INVESTIGATOR_291571]-1 RA and initiating tirzepatide at Visit 
2; see Section 4.1.[ADDRESS_355811] dose of study 
intervention.  
Demographics  X       Includes ethnicity (where allowed ), year of 
birth, sex, and race. 
Preexisting conditions and medical history, 
including relevant surgical history  X      Collect all conditions ongoing and relevant 
past surgical and medical history.  
Prior treatments for indication  X       Add details of T2D medication, which 
includes  medications used for T2D since 
diagnosis. 
Substance use (alcohol, caffeine, tobacco use) X       
Concomitant medications X X X X X X See Section 6.8. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
14 Study I8F-MC-GPIL Period I - 
Screening Period II  - Treatment Period Comments  
Visit Number  1 2 3 4 5 ED ED = early discontinuation  
Week Relative to Study Intervention S tart -3 0 4 8 12 I  
Visit Interval Tolerance (Days) 
+3/-7 0 Â±3 Â±3 Â±3  Flexibility is built into the screening visit to 
ensure adequate CGM session and 
appropriate timing for stoppi[INVESTIGATOR_291571]-1 RA and initiating tirzepatide at Visit 
2; see Section 4.1.1 . 
Fasting Visit   X   X X  
Adverse events (AEs)  X  X X X X X AEs are any events that occur after signing 
the informed consent. Collect  additional 
data for safety topi[INVESTIGATOR_291572]. See 
Section 8.3.[ADDRESS_355812] 5 min and before obtaining an 
ECG tracing and collection of blood samples for laboratory testing. See Section 8.2.2
. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
15 Study I8F-MC-GPIL Period I - 
Screening Period II  - Treatment Period Comments  
Visit Number  1 2 3 4 5 ED ED = early discontinuation  
Week Relative to Study Intervention S tart -3 0 4 8 12 I  
Visit Interval Tolerance (Days) 
+3/-7 0 Â±3 Â±3 Â±3  Flexibility is built into the screening visit to 
ensure adequate CGM session and 
appropriate timing for stoppi[INVESTIGATOR_291571]-1 RA and initiating tirzepatide at Visit 
2; see Section 4.1.[ADDRESS_355813] of care. 
12-lead ECG (local) X      Collect ECG before blood sample collection 
for laboratory testing if these procedures occur at the same visit.
 Partici pants should 
be supi[INVESTIGATOR_17044] 5 to 10 min 
before ECG collections and remain supi[INVESTIGATOR_291573].
 ECG 
6*B+.;.9.*=.-*==1.27?.<=20*=8;L<
discretion at any visit.  See Section 8.2.3 . 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
16 Study I8F-MC-GPIL Period I - 
Screening Period II  - Treatment Period Comments  
Visit Number  1 2 3 4 5 ED ED = early discontinuation  
Week Relative to Study Intervention S tart -3 0 4 8 12 I  
Visit Interval Tolerance (Days) 
+3/-7 0 Â±3 Â±3 Â±3  Flexibility is built into the screening visit to 
ensure adequate CGM session and 
appropriate timing for stoppi[INVESTIGATOR_291571]-1 RA and initiating tirzepatide at Visit 
2; see Section 4.1.1 . 
Fasting Visit   X   X X  
Dilated fundoscopic examination (local) X       An ophthalmologist or optometrist (if 
allowed by [CONTACT_1606]) will perform the 
examination.  Documentation of a previous 
exam ination F
-*B<9;28;=8<,;..72702<
acceptable to confirm eligibility.  Document 
the previous examination results in CRF. 
See Section  8.2.[ADDRESS_355814] as needed.  
BG meter, SMBG training  X       Train participant per provided instructions. 
Provide additional training as needed. 
Dispense BG meter/supplies X X X X   Dispense additional supplies, as needed. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
17 Study I8F-MC-GPIL Period I - 
Screening Period II  - Treatment Period Comments  
Visit Number  1 2 3 4 5 ED ED = early discontinuation  
Week Relative to Study Intervention S tart -3 0 4 8 12 I  
Visit Interval Tolerance (Days) 
+3/-7 0 Â±3 Â±3 Â±3  Flexibility is built into the screening visit to 
ensure adequate CGM session and 
appropriate timing for stoppi[INVESTIGATOR_291571]-1 RA and initiating tirzepatide at Visit 
2; see Section 4.1.1 . 
Fasting Visit   X   X X  
Return BG meter/supplies     X X  
CGM  sensor and insertion kit (14-day) 
application, training, and  education X      Apply and provide instructions to 
participants for at-home insertion for future 
visits . Additional training may occur as 
needed.  
Dispense CGM sensor and insertion kit (14-
day) X X  X   Dispense CGM sensor and insertion kit and 
instruct pa rticipant on dates to collect [ADDRESS_355815] the CGM device 14 days prior to their 
scheduled visit.  
CGM sensor (14-day) return and data 
download    X X  X  Site staff to collect at scheduled visit and 
perform  compliance assessment. If 
noncompliance is noted at Visit 3 , a repeat 
CGM session starting at Visit 3 can be 
performed without a protocol deviation. See 
Section 8.1.2 . 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
18 Study I8F-MC-GPIL Period I - 
Screening Period II  - Treatment Period Comments  
Visit Number  1 2 3 4 5 ED ED = early discontinuation  
Week Relative to Study Intervention S tart -3 0 4 8 12 I  
Visit Interval Tolerance (Days) 
+3/-7 0 Â±3 Â±3 Â±3  Flexibility is built into the screening visit to 
ensure adequate CGM session and 
appropriate timing for stoppi[INVESTIGATOR_291571]-1 RA and initiating tirzepatide at Visit 
2; see Section 4.1.1 . 
Fasting Visit   X   X X  
Study intervention injection training with 
demo device   X     Train participant with demo device prior to 
initial  injection. 
Review hypoglycemic events collected in the 
diary   X X X X X  
Participant Diary 
Participant diary dispensed X X X X   Diary includes blood glucose values, 
collection of intervention administration, information on dosing 
date/time, and 
hypoglycemia. See Section 8.1. 
Diary compliance check   X X X X X  
Diary return   X X X X X  
Laboratory Tests and Sample Collections 
Hematology X       
Hemoglobin A1C (HbA1c) X X X X X X  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
19 Study I8F-MC-GPIL Period I - 
Screening Period II  - Treatment Period Comments  
Visit Number  1 2 3 4 5 ED ED = early discontinuation  
Week Relative to Study Intervention S tart -3 0 4 8 12 I  
Visit Interval Tolerance (Days) 
+3/-7 0 Â±3 Â±3 Â±3  Flexibility is built into the screening visit to 
ensure adequate CGM session and 
appropriate timing for stoppi[INVESTIGATOR_291571]-1 RA and initiating tirzepatide at Visit 
2; see Section 4.1.1 . 
Fasting Visit   X   X X  
Clinical chemistry X X   X X Includes glucose testing. 
Lipid panel  X   X X  
Urinalysis X       
Serum pregnancy  X       Only for WOCBP and females with a 
history of tubal ligation. See Section  10.4.2 . 
Urine pregnancy (local)   X   X X Collect for WOCBP only. The result must 
be available prior to first dose of  
intervention. Perform additional pregnancy 
tests if there is clinical suspi[INVESTIGATOR_81178], or as required by [CONTACT_291588]. 
Follicle stimulating hormone (FSH) X      Optional; perform as needed to confirm 
postmenopausal status. See Section  10.4. 
Calcitonin  X        
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
20 Study I8F-MC-GPIL Period I - 
Screening Period II  - Treatment Period Comments  
Visit Number  1 2 3 4 5 ED ED = early discontinuation  
Week Relative to Study Intervention S tart -3 0 4 8 12 I  
Visit Interval Tolerance (Days) 
+3/-7 0 Â±3 Â±3 Â±3  Flexibility is built into the screening visit to 
ensure adequate CGM session and 
appropriate timing for stoppi[INVESTIGATOR_291571]-1 RA and initiating tirzepatide at Visit 
2; see Section 4.1.1 . 
Fasting Visit   X   X X  
Estimated glomerular filtration rate (eGFR) X      Calculate using CKD-EPI [INVESTIGATOR_12183]. 
Urinary albumin/creatinine ration (UACR) X       
Dosing 
Register visit with IWRS X X X X X X  
Dispense study inter vention using IWRS  X X X    
Observe participant administer study 
intervention   X      
Dispense ancillary supp lies to participant  X X X    
Participant returns unused study intervention 
and ancillary supplies    X X X X Where applicable as per local regulations. 
Assess study intervention compliance   X X X X  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
21 Abbreviations: BG = blood glucose; CKD-EPI = chronic kidney dise ase - epi[INVESTIGATOR_8261]; CGM = continuous glucose moni toring; CRF = case 
report form; ECG = electrocardiogram; GLP-1 RA = glucagon-like pe ptide-[ADDRESS_355816]; IWRS = interactive web-response syst em; PI = Principal 
Investigator; SoA = Schedule of Activities; SMBG = self-monitoring of blood glucose; T2D = Type 2 diabetes; WOCBP = women of ch ildbearing potential.  
$SSURYHGRQ$XJ*[ADDRESS_355817] to comprehensive lifestyle interventions (Buse et al. 2020; Garber et al. 2020; ADA 2022). They vary in terms of pharmacokinetics, dosing regimen, and clinical effects (Neumiller 2011). Switching between GLP-1 RAs occurs to improve HbA1c control, promote additional weight reduction, or mitigate side effects (Almandoz et al. 2020; Jain et al. 2021a). Additionally, patient 
preference for different medication attributes or pharmacy coverage may also drive switching 
between agents. 
Tirzepatide Tirzepatide is a recently approved single molecu le that acts as glucose-dependent insulinotropic 
polypeptide (GIP) and GLP-[ADDRESS_355818], wh ich has demonstrated an ability to reduce 
HbA1c and body weight in adults with T2D across all 3 therapeutic doses: 5, 10, and 15 mg (Del 
Prato et al. 2021; FrÃ­as et al. 2021; Ludvik et al. 2021; Rosenstock et al. 2021; Dahl et al. 2022). It is more efficacious in reducing HbA1c and promoting weight reduction than dulaglutide and semaglutide in people not on previous GLP-1 RA therapy (FrÃ­as et al. 2018; FrÃ­as et al. 2021). 
2.1. Study Rationale 
No study has investigated the effects of switchin g from GLP-[ADDRESS_355819] when switching from a 
GLP-1 RA to tirzepatide 5 mg but does not evaluate long-term efficacy, optimal dosing, or comparative improvement to other regimens. 
Prior exposure to a GLP-1 RA is associated with less frequent GI intolerance when switching 
between GLP-1 RAs (Hepprich et al. 2021; Jain et al. 2021b). Therefore, this study will describe 
an alternative way to switch from a GLP-[ADDRESS_355820] 
12 weeks for the targeted study population. 
2.2. Background 
Phase 3 clinical studies 
Clinical reductions in HbA1c and body weight 
In a series of 5 global Phase 3 SURPASS studies, tirzepatide demonstrated clinically meaningful 
reductions in HbA1c and body weight, which were greater than placebo and active comparators 
(Del Prato et al. 2021; FrÃ­as et al. 2021; Ludvik et al. 2021; Rosenstock et al. 2021; Dahl et al. 2022). These treatment effects were sustained up to 104 weeks (Del Prato et al. 2021). 
$SSURYHGRQ$XJ*[ADDRESS_355821] circumference, volume of abdominal visceral and SC adipose tissue, 
and fasting lipid profile (Del Prato et al. 2021; FrÃ­as et al. 2021; Ludvik et al. 2021; Rosenstock 
et al. 2021; Battelino et al. 2022; Dahl et al. 2022; Gastaldelli et al. 2022). 
Common adverse events 
Overall, the safety and tolerability profiles are similar to GLP-[ADDRESS_355822] common AEs seen in the tirzepatide-
treated participants. 
Hypoglycemia events 
In line with the ability of tirzepatide to lowe r blood glucose in a glucose-dependent manner, the 
overall incidence of clinically significant or severe hypoglycemia attributable to tirzepatide was 
low. The risk of clinically significant hypoglycemia or severe hypoglycemia was higher when 
tirzepatide was used in combination with insulin glargine or sulfonylurea, as has been observed with GLP-1 RAs (Del Prato et al. 2021; FrÃ­as et al. 2021; Ludvik et al. 2021; Rosenstock et al. 2021; Dahl et al. 2022). 
2.3. Benefit/Risk Assessment 
Overall, the known benefits associated with tirzepatide in people with T2D outweigh known risks associated with the therapy. 
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of tirzep atide may be found in the IB and  package insert (Mounjaro
E 
USPI [WWW]). 
2.3.1. Risk Assessment 
Management of risks 
Sections 5.1, 5.2, 8.2, and 8.3 address known potential risks associated with tirzepatide. 
2.3.2. Benefit Assessment 
The potential benefits from participation in this study include improved glycemic control, weight 
loss, and continued expert medical care for the study duration. 
Participants may benefit by [CONTACT_291586] l health information, routine safety assessments, 
lifestyle management counseling, and frequent engagement with health care providers during the 
study, which provide opportunities for coaching and support. Following study completion, the participantLs data from CGM, describing how their glucose responds to day-to-day activities, will 
be available for future medical decision-making. 
2.3.3. Overall Benefit Risk Conclusion 
The safety and efficacy profile seen to date for tirzepatide supports the overall benefit risk for 
participants in this study. Considering the measures taken to minimize risk to participants in this 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
24 study, the potential risks identified in association with tirzepatide are justified by [CONTACT_291589] T2D.  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
25 3. Objectives, Endpoints, and Estimands 
Objectives Endpoints 
Primary  
To demonstrate that participants with T2D  switching 
from a stable dose of GLP -1 RA to tirzepatide 5 mg 
QW ha ve an improvement in HbA1c at Week 12 
compared to baseline   Change from baseline in HbA1c  
Secondary  
To evaluate the changes in CGM-assessed TAR from 
baseline  at Week 4 and at Week 12 Change  from baseline in  
 Percentage of time per day that CGM-derived 
values are >180 mg/dl (10 mmol/L)  
 Duration of time in minutes per day that CGM-derived values are >180 mg/dl (10 mmol/L) 
To evaluate the change in FSG from baseline at Week 
12  Change from baseline in FSG 
To evaluate the changes from baseline in weight at 
Week  12  Change from baseline in weight 
Exploratory  
To evaluate changes in CGM -derived measures from 
baseline over the course of 12 weeks  Change from baseline in 
o standard CGM metrics (TIR, TBR, GV) 
o time in TITR 
o composite of all in-ranges 
o mean 24-hr daily blood glucose 
o estimated post-prand ial glucose excursion  
o estimated fasting glucose 
Abbreviations: CGM = continuous glucose monitoring; FSG = fasting serum glucose; GLP-1 RA = glucagon-like 
peptide-[ADDRESS_355823]; GV = glycemic variability; HbA1c = hemoglobin A1c; QW = once-weekly; 
T2D = type-2 diabetes; TAR = time above range (>180 mg/dl or >10 mmol/L); TBR = time below range (F
 60	-58;F
  mmol/L); TIR = time-in-range (71 to 180 mg/dL or 3.9 to 10 mmol/L); TITR = time in tight 
target range (71 to 140 mg/dL or 3.9 to 7.8 mmol/L);  
Primary estimands 
The primary estimand in this study is the efficacy estimand. 
The efficacy estimand focuses on the treatment effe ct if participants continued to receive the 
study treatment without prohibited medication. This  estimand will be used in publications to 
inform prescribers or physicians. 
$SSURYHGRQ$XJ*[ADDRESS_355824] is 
What is the change in HbA1c from baseline to Week 12 in participants with T2D, 
regardless of changes in background OAM, and assuming that participants continue to 
take treatment without use of prohibited medication? 
This estimand is described by [CONTACT_6570]: 
 Population: participants with T2D on a GLP-1 RA who may benefit from additional 
therapy regardless of background OAM. Further details can be found in Section 5. 
 Endpoint: changes from baseli ne to Week 12 in HbA1c. 
 Treatment condition: treatment with tirzepatide regardless of changes to the background 
OAM. Further details on study treatment can be found in Section 6. 
 Intercurre7=.?.7=<8/27=.;.<=J&;.*=6. 7=-2<,87=27>*=287/8;*7B;.*<8 7K*7-J72=2*=287
of prohibited medication K@255+.*--;.<<.-><270=1./8558@270<=;*=.02.<  
o As if participants stay on the treatment (hypothetical strategy) 
o As if participants did not receive prohibi ted medication (hypothetical strategy). 
 Population-level summary: difference in m ean changes within treatment condition. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
27 4. Study Design 
4.1. Overall Design 
SURPASS-SWITCH-2 is an open-label, single-arm, multicenter, multinational, Phase 4 study to 
assess the changes in glycemic control when switching from a stable dose of a GLP-1 RA 
directly to tirzepatide 5 mg in participants with T2D. 
This study includes a screening peri od and a 12-week treatment period. 
See the SoA (Section 1.3) for additional details about the study periods and visit-specific 
assessments, including assessments needed at an ED visit. 
4.1.1. Design Outline 
Period I: Screening 
Preparation for the switch from GL P-1 RA medication to tirzepatide 
The investigator will determine the pa ;=2,29*7=L s current GLP-[ADDRESS_355825] 3 days prior to Visi t 2 but no more than 10 days prior to Visit 2. 
Training for the study-supplied SMBG monit or and testing frequency recommendations will 
occur. Training for the CGM sensor and insertion device, including suggestions for successful 
device maintenance, will also occur in conjunction with the insertion of the CGM sensor for the baseline measurement session. 
Period II: Treatment Period 
Visit 2 Treatment Initiation 
Participants arrive to the clinic in the fasting state. See Section 6.1 for intervention details. 
This is the general flow for Visit 2: 
 Participant returns screening CGM sensor for compliance review and data upload 
 Study personnel confirm enrollment criteria 
 Study personnel complete all required visit procedures, including the collection of vital 
signs, all baseline procedures,  and sample collection, and 
 Treatment initiation for el igible participants 
Study intervention training 
Study personnel will provide appropriate training for  the use of the tirzepatide SDP. The training 
can be provided using a demonstration device, if av ailable. This training will be repeated at 
subsequent visits, as needed. 
$SSURYHGRQ$XJ*[ADDRESS_355826]-<9.,2/2,J27<=;>,=287</8;><.K27/8;6*=287=8
the participants upon request, if available. 
First tirzepatide dose 
Study personnel will observe as the participant injects the first dose of tirzepatide. The remaining 
injections will occur at participant Ls home. The date and time of the first dose of tirzepatide 
should be recorded on the CRF. Additionally, all medication doses administered at home should 
be captured, including date and time, in the participantL s diary and subsequently recorded in the 
CRF. 
Visit 5 (Week 12) Treatment Period or ED Visit 
&1.27?.<=20*=8;@255-.=.;627.*9*;=2,29*7=L<=;*7<2=287/;86<=>-B=;.*=6.7==8*78=1.;-2*+.= es 
treatment, including re-initiation of baseline GLP-[ADDRESS_355827] GI 
intolerance occurs after initiating tirzepatide therapy. 
The 12-week study period provides several ti mepoints to assess changes in intermediate 
glycemic control via CGM sensor and then overa ll assessment of glycemic control with change 
in HbA1c at 12 weeks. 
Open-label design 
A single-arm study supports an open-label design. 
Demographics collection 
In this study, collection of demographic information includes race and ethnicity as allowed per 
local regulations. The scientific rationale is based on the need to assess variable response in safety and/or efficacy based on race or ethnicity. This question can be answered only if all the relevant data are collected. 
4.3. Justification for Dose 
The current US product label specifies that tirzep atide should be started at 2.5 mg (initiation 
dose) and escalated to 5 mg after 4 weeks. This dosing was based on GLP-1 RA naive 
participants to optimize tolerability and clinical efficacy. For participants with T2D who are 
$SSURYHGRQ$XJ*[ADDRESS_355828] scheduled procedure shown in the SoA. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
30 5. Study Population 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
5.1. Inclusion Criteria 
Participants are eligible to be included in the study only if all of the following criteria apply: 
Age 
1. Are [ADDRESS_355829] an HbA1c G6.5% (G48 mmol/mol) to F0% (F75 mmol/mol) as determined by [CONTACT_23283] [ADDRESS_355830] been on a stable treatment dose of 1 of the listed GLP-1 RAs for G3 months prior to 
Visit 1: 
o liraglutide 1.2 or 1.8 mg QD 
o dulaglutide 0.75, 1.5, 3, or 4.5 mg QW, or 
o injectable semaglutide 0.5, 1, or 2 mg QW. 
5. No treatment with OAM or on stable doses (for at least 3 months before Visit 1) of up to 3 OAM. The OAM may include metformin (at least 1000 mg/day), SGLT-2i, thiazolidinediones, or N-glucosidase inhibitors. 
Weight 
6. *?. G  kg/m2 at Visit 1. 
Sex and contraceptive/barrier requirements 
7. Contraceptive use by [CONTACT_291590]. For the 
contraception requirements of this protocol, see Section 10.4, Appendix 4. 
Informed consent 
8. Are capable of giving signed informed  consent as described in Section 10.1.3 , 
Appendix 1, which includes compliance with the requirements and restrictions listed in 
the ICF and in this protocol. 
Other inclusion criteria 
9. Are reliable and willing to make themselves available for the duration of the study and are willing and able to follow study procedures as required, including compliance with 
CGM sensor and insertion device (defined in Section 4.1.1). 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
31 5.2. Exclusion Criteria 
Participants are excluded from the study if any of the following criteria apply at screening: 
Medical conditions 
10. Have T1D. 
11. Have a history of chronic or acute pancreatitis any time prior to Visit 1. 
12. Have a clinical history of 
o proliferative diabetic retinopathy 
o diabetic maculopathy, or 
o nonproliferative diabetic retinopathy that requires acute treatment. 
13. Are at high risk for CVD in =1.27?.<=20*=8;L<89272878;1*?. a history of any of these 
CV conditions within 60 days prior to Visit 1: 
o myocardial infarction 
o percutaneous coronary reva scularization procedure 
o carotid stenting or surgical revascularization 
o nontraumatic amputation 
o peripheral vascular procedure (e.g., stenting or surgical revascularization) 
o cerebrovascular accident (stroke), or 
o hospi[INVESTIGATOR_126042]. 
14. Have NYHA Functional Classification Class IV congestive heart failure. 
15. Have a history of ketoacidosis or hyperosmolar state or coma. 
16. Have a history of severe hypoglycemia or hypoglycemia unawareness within the 
[ADDRESS_355831] during the course of the study gastric by[CONTACT_6476] (bariatric) surgery or restrictive bariatric surgery (for example, Lap-Band
Â®), or chronically take 
drugs that directly affect GI motility. 
19. Have acute or chronic hepatitis, signs and symptoms of any liver disease other than 
NAFLD, or ALT level >3.[ADDRESS_355832] for the reference range, as determined by [CONTACT_291591]. Participants with NAFLD are eligible to participate if =1.2;&5.?.52<F

=26.<=1.'!/8;=1.;./ erence range. 
20. Have an estimated glomerular fi ltration rate <30 mL/min/1.73 m
2, or lower than the 
country-specific threshold for discontinuing metformin therapy (if used) or SGLT-2i (if used) per local label, calc ulated by [INVESTIGATOR_82351]-Epi[INVESTIGATOR_291574] 1. 
21. Have evidence of a significant, uncontrolled endocrine abnormality, for example, thyrotoxicosis or adrenal crises, in the opi[INVESTIGATOR_871]. 
22. Have family or personal history of MTC or MEN2. 
23. Have a s.;>6,*5,2=87275.?.58/G
 ng/L, as determined by [CONTACT_82408] 1. 
24. Have known or suspected hypersensitivity to study product(s) or related products. 
25. Have evidence of a significant, active autoimmune abnormality, for example, lupus or rheumatoid arthritis, that, in the opi[INVESTIGATOR_871], is likely to require concurrent 
treatment with systemic glucocorticoids in the next 4 months. 
$SSURYHGRQ$XJ*[ADDRESS_355833] had a transplanted organ or awaiting an organ transplant. Exception: corneal 
transplants (keratoplasty). 
27. Have a history of an active or untreated malignancy or are in remission from a clinically 
significant malignancy for less than 5 years. 
Exceptions: 
o basal or squamous cell skin cancer 
o in situ carcinomas of the cervix, and 
o in situ or Grade 1 (for example,  Gleason 6 or lower) prostate cancer. 
28. Have a history of any other condition, such as known drug, alcohol abuse, or psychiatric 
disorder that, in the opi[INVESTIGATOR_871], may preclude the participant from following and completing the protocol. 
29. Have any chronic hematological condition that may interfere with HbA1c measurement, such as hemolytic anemias and sickle cell disease. 
30. Have a history or presence of an underlying disease, or surgical, physical, or medical condition that, in the opi[INVESTIGATOR_871], would potentially affect participant safety within the study or interfere with the interpretation of data. 
Prior/concomitant therapy  
31. Have been treated with other glucose-lowering agents, not listed in Inclusion Criterion 5, in the 3 months prior to Visit 1. Exception: use of insulin for gestational diabetes or short-term use (F 14 days) for acute 
conditions, such as acute illness, hospi[INVESTIGATOR_059], or elective surgery within the [ADDRESS_355834] of prohibited medications. 
33. Are receiving chronic (>2 weeks or 14 days) systemic glucocorticoid therapy or have received such therapy within 1 month of Visit 1 or between Visits 1 and 2. Exceptions: topi[INVESTIGATOR_2855], intraocular, intranasal, or inhaled preparations.  
Prior/concurrent clin ical study experience 
34. Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study. 
35. Have participated, within the last [ADDRESS_355835]-party involved in study who require 
exclusion of their employees. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
33 38. Are investigator site personnel directly affiliated with this study and/or their immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted. 
39. Female participants who are pregnant or breastfeeding or intending to become pregnant. 
5.3. Lifestyle Considerations 
Diabetes management counseling 
Per the SoA (Section 1.3), qualified medical staff will provide diabetes management counseling, 
which will include instructions on diet and exercise and education about the signs, symptoms, 
and management of hypoglycemia or hyperglycemia, should it occur. 
Participant exercise and diet 
Participants should continue their usual exercise habits and generally follow a healthy meal plan 
(with consistent meal size and time of day) throughout the course of the study. 
Participants should not initiate an organized diet or exercise (weight reduction) program during 
the study other than the lifestyle and dietary measures for diabetes treatment. 
Dietary counseling may be reviewed throughout the study, as needed. Blood product donation 
Study participants should be instructed not to donate blood or blood products during the study. 
5.4. Screen Failures 
A screen failure occurs when a participant who cons ents to participate in the clinical study but is 
not subsequently assigned to study interventio n. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the CONSORT 
publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any SAE. 
Individuals who do not meet the criteria for participation in this study (screen failure) may not be 
rescreened. 
5.5. Criteria for Temporarily Delaying Enrollment of a Participant 
This section is not applicable to this study. All entry criteria must be met within the specified 
visit intervals in the SoA (Section 1.3). 
See Section 10.[ADDRESS_355836] during exceptional circumstance. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
34 6. Study Intervention(s) and Concomitant Therapy 
Study intervention is defined as any investigational intervention( s), marketed product(s), 
placebo, or medical device(s) intended to be administered to or used by a study participant 
according to the study protocol. 
6.1. Study Intervention(s) Administered 
The planned treatment is ti rzepatide 5 mg (Section 6.5 ). 
This table lists the interventions used in this clinical study. 
Intervention Name  [CONTACT_134143] (LY3298176)  
Dosage Level(s)  5 mg 
Route of Administration  Subcutaneous using an SDP 
Authorized as Defined by [CONTACT_291592]: SDP = single-dose pen. 
Administration and timing of dose administration 
Tirzepatide is administered QW by [CONTACT_57982]. There are no restrictions on the time of day 
each weekly dose of study intervention is given, but it is advisable to administer the SC 
injections on the same day and same tim e each week, with or without meals. 
Anatomical location of injections 
Acceptable locations for injection include the abdomen, thigh, or upper arm if another person 
gives the injection. 
Participants should rotate injection sites from one  injection to the next, even when injecting 
within the same region. 
Packaging and labeling 
Tirzepatide will be supplied by [CONTACT_291593]. SDPs will be packaged in ca rtons to be dispensed and will be labeled as 
appropriate for country requirements. 
Tirzepatide will be dispensed at the st udy visits summarized in SoA (Section 1.3 ). 
Returned tirzepatide should not be re-dispensed to the participants. 
Missed doses 
If a dose is missed, the participant should take their dose as soon as possible, within 4 days 
(96 hours) after the missed dose. If more than [ADDRESS_355837] passed, that dose should be skipped, 
and the next dose should be taken at the appropriate time. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
35 6.1.1. Medical Devices 
Tirzepatide will be provided as a drug/device combination product in a prefilled SDP for the 
administration of study intervention. A new SDP will be used for each injection. 
Medical devices for tirzepatide used in this study are manufactured by [CONTACT_291594] a third-party. 
Instructions for medical device use for tirzepatide are provided in the Instructions for Use. 
All Product Complaints, including malfunction, use error, and inadequate labeling, shall be 
documented and reported by [CONTACT_291595] (see Section 
8.3) and appropriately managed by [CONTACT_456]. 
6.1.2. Rescue Therapy 
The incidence of severe hyperglycemia in the Phase 3 SURPASS clinical program was low for 
participants randomly assigned to tirzepatide 5 m g. This study will include participants with a 
baseline A1c F9.0%, which further decreases the possibility of severe hyperglycemia occurring 
in the study population within a 12-week treatment period. 
No rescue therapy will be initiated, but at the investigators L discretion, insulin can be used on a 
short-term basis ( F14 days) for acute conditions, such as acute illness, hospi[INVESTIGATOR_059], or elective 
surgery. This treatment will not be considered resc ue therapy, and participant will continue in the 
study as long as the tirzepatide treatment continue s. Insulin use must be reported in the CRF as 
concomitant medication, not as rescue therapy.  
6.1.3. Background Therapy 
Participant eligibility requires them to be on a stable dose of a GLP-1 RA as listed in the 
inclusion requirements (See section 5.1). The GLP-[ADDRESS_355838] be stored in a secure, environmentally controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions with access limited 
to the investigator and authorized study personnel. 
The investigator or authorized study personnel are responsible for study intervention 
accountability, reconciliation, and record maintenance, that is, receipt, reconciliation, and final 
disposition records. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
36 Further guidance and information for the final disposition of unused study interventions are 
provided in the Pharmacy Manual. 
Study intervention will be dispensed at the study visits summarized in SoA. 
6.3. Measures to Minimize Bias: Randomization and Blinding 
Randomization 
This is a descriptive study with baseline-to-endpoint comparisons; no randomization will occur. 
Blinding 
This is an open-label study. 
6.4. Study Intervention Compliance 
Participant compliance with study intervention will  be assessed at visits summarized in the SoA. 
The investigator site personnel will review the amount of unused study intervention returned in 
addition to injection information provided by [CONTACT_291596]. Study intervention compliance will 
be recorded for each visit interval when study intervention is dispensed. 
If a participant is considered poorly compliant with their study procedures, for example, missed 
visits or specific diagnostic tests, they will be retrained as needed by [CONTACT_51015]. 
6.5. Dose Modification 
This study is designed to assess the transition from a GLP-1 RA to tirzepatide 5 mg, and hence 
no dose escalation will be employed during the trial. The goal is to initiate tirzepatide at 5 mg on 
Visit 2 (Week 0) and maintain until Visit 5 (Week 12). 
6.5.1. Management of Participants with Gastrointestinal Symptoms 
The dose scheme is designed to assess the glycemic transition from a GLP-1 RA directly to 5 mg 
and assess the development of intolerable GI symptoms. Every effort should be made by [CONTACT_291597] 5 mg dose throughout the trial. 
This table describes steps the investigator shoul d follow to mitigate GI symptoms and manage 
participants with intolerable GI AEs.  
STEP 1 Advise participants to eat smaller meals, for examp le, splitting 3 daily meals into 4 or more smaller 
meals, and to stop eating when they feel full. 
STEP 2 Continue STEP 1 + 
Prescribe symptomatic medication, for example, anti -emetic or anti- diarrheal medication, per local 
country availability and individual participant needs. Use of symptomatic medication  should be 
captured as concomitant medication in the CRF. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
37 STEP 3 Continue STEP 1 + STEP 2 + 
Temporarily interrupt tirzepatide; om it [ADDRESS_355839] despi[INVESTIGATOR_10902], the investigator may 
discontinue study drug intervention. 
Abbreviations: CRF = case report form; GI = gastrointestinal. 
6.6. Continued Access to Study Intervention after the End of the Study 
The sponsor will not provide participants with any ongoing supplies or study intervention after 
they have completed the study treatment period or permanently discontinued the study intervention. 
6.7. Treatment of Overdose 
6.7.1. Tirzepatide Overdose 
Tirzepatide overdose was defined as administration of more than a total of [ADDRESS_355840] the medical monitor immediately 
P evaluate the participant to determine, in consultation with the medical monitor, 
whether study intervention should be interrupted 
P closely monitor the participant for any AE/SAE and laboratory abnormalities as 
medically appropriate until, for example, study intervention no longer has a 
clinical effect, and 
 initiate ap9;89;2*=.<>998;=2?.=;.*=6.7=*,, 8;-270=8=1.9*;=2,29*7=L<, 5272,*5<207<*7-
symptoms. 
6.8. Prior and Concomitant Therapy 
6.8.1. Allowed Concomitant Therapy 
Participants are allowed to use concomitant medications that they require during the study, 
except certain medications that may interfere with the assessment of efficacy and safety characteristics of the study intervention. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
38 6.8.2. Changing Concomitant Therapy 
Reduction and/or discontinuation of concomitant antihyperglycemic treatments other than study 
intervention are described in Section 6.1.3. 
Changes in other concomitant medications will be allowed at the discretion of the investigator as clinically indicated in accordance with local standa rd of care and professional society guidelines. 
Authorized study personnel should consult the med ical monitor if there are any questions about 
concomitant therapi[INVESTIGATOR_226]. 
6.8.3. Concomitant Therapy Data Collection 
Any concomitant medication or vaccine including  over-the-counter or prescription medicines, 
vitamins, and/or herbal supplements that the particip ant is receiving at the time of enrollment or 
receives during the study; authorized study personnel should collect 
 name [CONTACT_2100], vaccine, or therapy 
 reason for use 
 dates of administration, incl uding start and end dates, and 
 dosage information, including dose and frequency for concomitant therapy of 
special interest. 
Contact [CONTACT_291598]. 
6.8.4. Prohibited Concomitant Medications 
See Section 5 for prohibited antihyperglycemic medications. 
Medications intended to promote weight loss are prohibited in this study. This includes 
prescribed, over-the-counter, or alternative remedies. Examples include, but are not limited to 
 Liraglutide 3.0 mg  Topi[INVESTIGATOR_052] 
 Semaglutide 2.4 mg  Orlistat 
 Sibutramine  Phenylpropanolamine 
 Mazindol  Phentermine 
 Lorcaserin  Phentermine or topi[INVESTIGATOR_81063], or 
 Naltrexone or bupropi[INVESTIGATOR_2394]  Pramlintide 
 Zonisamide  
6.8.5. Allowed Antihyperglycemic Treatm ents other than Tirzepatide 
No new additional antihyperglycemic treatment is pe rmitted in this study other than tirzepatide. 
As noted in Section 6.1.[ADDRESS_355841] be reported in the CRF as concomitant medication, not as rescue therapy. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
39 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal 
Discontinuation of specific sites or of the study as a whole are handled as part of Section 10.1.9, 
Appendix 1. 
7.1. Discontinuation of Study Intervention 
When necessary, a participant may be permanentl y discontinued from tirzepatide. If so, the 
participant will remain in the study and follow procedures for remaining study visits, as shown in 
the SoA (Section 1.3). 
A participant should be permanently discontinued from study intervention if 
 the participant becomes pregnant during the study (see Section 8.3.2) 
 the participant is diagnosed with T1D or LADA 
 the participant requests to discontinue intervention 
 the participant develops confirmed pancreatit is; if not confirmed, study intervention may 
be restarted 
 the participant is diagnosed with MTC, C-cell hyperplasia, or multiple endocrine 
neoplasia syndrome 
 the participant is diagnosed with an active malignancy or if a previously treated malignancy becomes known after enrollment 
 the participant experiences a significant study intervention-related hypersensitivity reaction after administration of study intervention 
 any other AE, SAE, or clinically significant laboratory value for which the investigator believes that permanent study intervention discontinuation is the appropriate measure to be taken, or 
 in the opi[INVESTIGATOR_871], the participant should permanently discontinue the study intervention for safety reasons. 
Participants who stop tirzepatide permanently will receive another locally approved 
antihyperglycemic medication, if needed per clinic al judgment of investigator, and will continue 
participating in the study according to the protocol to collect all planned measurements per SoA (Section 1.3), Adverse Events (Section 8.3), and Safety Assessments (Section 8.2) of this 
protocol. 
The choice of antihyperglycemic medication, in cluding restarting the prestudy GLP-1 RA, will 
be at the discretion of the investigator. The investigators should follow current published 
standards of care from the American Diabetes Association and/or a consensus report by [CONTACT_291599] (ADA 2022, 
Buse et al. 2020). 
The new antihyperglycemic medication will be  recorded on the CRF for antihyperglycemic 
medications. 
$SSURYHGRQ$XJ*[ADDRESS_355842] elevations in participants with normal or 
near-normal baseline liver tests 
In study participants with normal or ne ar normal baseline liver tests (ALT, AST, 
ALP <1.5x ULN), the study drug should be interrupted  and close hepatic monitoring initiate 
(see Section 8.2.7) if 1 or more of these conditions occur: 
Elevation Exception 
ALT or AST >8x ULN  
ALT or AST >5x ULN for more than [ADDRESS_355843] >3x ULN and either TBL >2x ULN or INR >1.5  8;9*;=2,29*7=<@2=125+.;=L<<B7-;86.  
If baseline direct bilirubin is >0.5  mg/dL, 
then doubling of direct bilirubin should be 
used for drug interruption decisions rather than TBL>2x ULN. 
ALT or AST >3x ULN with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)  
ALP >3x ULN, when the source of increased ALP is the liver  
ALP >2.5x ULN and TBL > 2x ULN  8;9*;=2,29*7=<@2=125+.;=L<<B7-;86.  
If baseline direct bilirubin is >0.5  mg/dL, 
then doubling of direct bilirubin should be 
used for drug interruption decisions rather than TBL>2x ULN. 
ALP >2.5x ULN with the appearance of fatigue, nausea, 
vomiting,  right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)  
Source: FDA Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation, July 2009 and 
other consensus guidelines, with minor modifications 
Abbreviations: ALP = alkaline phosphatase; ALT = alanine am inotransferase; AST = aspartate aminotransferase; 
INR = international normalized ratio; TBL = total b ilirubin level; ULN = upper limit of normal. 
Interrupting study drug based on elevated li ver tests in participants with abnormal 
baseline liver tests In study participants with abnormal baseline liver tests (ALT %&#GA'!=1.<=>-B
drug should be interrupted  if 1 or more of these conditions occur: 
Elevation Exception 
ALT or AST >4x baseline  
ALT or AST >3x baseline for more than [ADDRESS_355844] >2x baseline and either TBL >2x ULN or INR >1.5  8;9*;=2,29*7=<@2=125+.;=L<<B7-;86.  
If baseline direct bilirubin is >0.5  mg/dL, 
then doubling of direct bilirubin should be 
used for drug interruption decisions rather than TBL>2x ULN. 
ALT or AST >2x baseline with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
41 ALP >2.5x baseline, when the source  of increased ALP is the liver  
ALP >2x baseline and TBL > 2x ULN  8;9*;=2,29*7=<@2=125+.;=L<<B7-;86.  
If baseline direct bilirubin is >0.5  mg/dL, 
then doubling of direct bilirubin should be 
used for drug interruption decisions rather than TBL>2x ULN. 
ALP >2x baseline with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)  
Source: FDA Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation, July 2009 and 
other consensus guidelines, with minor modifications 
Abbreviations: ALP = alkaline phosphatase; ALT = alanine am inotransferase; AST = aspartate aminotransferase; 
INR = international normalized ratio; TBL = total b ilirubin level; ULN = upper limit of normal. 
Resuming study drug afte r elevated liver tests 
Resumption of the study drug can be considered only in consultation with the Lilly-designated 
medical monitor and only if the liver test results return to baseline and if a self-limited, non-drug 
etiology is identified. Otherwise, the study drug should be discontinued. 
7.1.2. Temporary Discontinuation of Study Intervention 
The investigator may temporarily interrupt tirzepatide due to 
 an AE 
 clinically significant laboratory value 
 hospi[INVESTIGATOR_291575] 
 travel or shortage of study treatment supply, or 
 any other event necessitating temporary discontinuation of tirzepatide. 
If tirzepatide is temporarily interrupted for reasons  other than tolerability, participants should be 
encouraged to restart tirzepatide as soon as it is safe to do so. 
Every effort should be made by [CONTACT_291600], as soon as it is safe to do so. 
If the tirzepatide interruption is due to intolerable persistent GI AE, such as nausea, vomiting, or 
diarrhea, the participant should be treated as suggested in Section 6.5.1. 
Recording temporary discontinuation of tirzepatide 
The dates of study intervention interruption and re start must be documented in source documents 
and entered on the CRF. 
Participant noncompliance should not be recorded as interruption of study intervention on the 
CRF.  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
42 7.2. Participant Discontinuation/Withdrawal from the Study 
Discontinuation is expected to be uncommon. 
A participant may withdraw from the study 
 at any time at the 9*;=2,29*7=L<8@7;.:>.<=  for any reason or without providing any 
reason 
 if the participant is diagnosed with T1D or LADA 
 if the participant is diagnosed with a malignancy after enrollment 
o Exceptions : 
Â basal or squamous cell skin cancer 
Â in situ carcinomas of the cervix, and 
Â in situ or Grade 1 (for example, Gleason 6 or lower) prostate cancer. 
 at the discretion of the investigator for safe ty, behavioral, compliance, or administrative 
reasons 
 if a female participant becomes pregnant; see Section 8.3.2 
 if enrolled in any other clinical study invol ving an investigational product, or enrolled in 
any other type of medical research judged not to be scientifically or medically compatible 
with this study 
 if the participant, for any reason, requires treatment with a therapeutic agent that is prohibited by [CONTACT_291601]. In this case, discontinuation from the study occurs prior to introduction of the new agent. 
At the time of discontinuing from the study, if possible, the participant will complete procedures 
for an ED visit, as shown in the SoA (Section 1.3). 
If the participant has not already discontinued the study intervention, the participant will be 
permanently discontinued from the study intervention at the time of the decision to discontinue the study. 
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of consent. 
If a participant withdraws from the study, the participant may request destruction of any samples 
taken and not tested, and the investigator must document this in the site study records. 
7.3. Lost to Follow-Up 
A participant will be considered lost to follo w-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298]. Site personnel or designee are 
expected to make diligent attempts to contact [CONTACT_291602] a scheduled visit 
or were otherwise unable to be followed up by [CONTACT_779]. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
43 8. Study Assessments and Procedures 
Study procedures and their timing are summarized in the SoA (Section 1.3). 
Immediate safety concerns should be discusse d with the sponsor immediately upon occurrence or 
awareness to determine if the participant shoul d continue or discontinue study intervention. 
Adherence to the study design requirements, including those specified in the SoA (Section 1.3), 
is essential and required for study conduct. 
All screening evaluations must be completed and reviewed to confirm that potential participants 
meet all eligibility criteria. The investigator will maintain a screening log to record details of all 
participants screened and to confirm eligibility or record reasons for screening failure, as 
applicable. 
8.1. Efficacy Assessments 
Primary efficacy assessment  
The primary efficacy measurement in this study is change in HbA1c from baseline to Week 12 (Section 1.3). 
Other efficacy assessments  
Other efficacy assessments include change in weight, and fasting serum glucose from baseline to 
Week 12. CGM-derived assessments  will be assessed over the course of this 12-week study, 
including specific endpoints at 4 and 12 weeks. 
8.1.1. Self-Monitoring of Blood Glucose (SMBG) 
Participants must use only the study-provided monitors, provided per local guidelines, during the 
study. 
Glucometer for participant use during the study 
Participants will receive a glucometer and relat ed testing supplies for use during the study. 
Glucometer training 
Site personnel will train the participant on correct use of the glucometer for self-monitoring 
blood glucose and reporting of hypoglycemia data. 
When to measure FBG during the study 
Site personnel will train the participant to measure FBG daily when possible, and a minimum of 
2 times per week using the study-provided glucometer. 
The FBG should be measured upon waking in the morning, prior to food or caloric beverage 
intake. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
44 Glucometer data transfer 
The study-provided glucometer will wirelessly transmit blood glucose measurements to the 
9*;=2,29*7=L<diary. Site personnel will be able to view SMBG data that have been transmitted to the diary through a web-based portal as well as any reported events of hypoglycemia.  
SMBG for hypoglycemia or hyperglycemia 
Participants should perform SMBG with the study-provided BG meter whenever hypoglycemia 
is experienced or suspected, with or without symptoms. SMBG should also be measured when there is perceived or increased risk related to changes in dietary intake, or physical activity. 
Participants may perform SMBG more frequently to check for instances of hyperglycemia, or as directed by [CONTACT_093]. Investigators may also instruct participants to collect SMBG, at time 
points other than at fasting, to evaluate glyc emic control or based on the investigator clinical 
judgment. 
8.1.2. Continuous Glucose Monitoring 
The study-provided CGM sensor will be used in blinded mode during the study. The blinded 
CGM sensor will not display the sensor glucose readings to the participant or investigator, and 
high and low glucose alerts will not be available to the participant. 
Participants are not allowed to use a personal, non-study CGM device during the study or 
connect the CGM sensor to a personal smartphone, smartphone application, or other system. 
Continuous glucose monitoring procedure 
At Visit 1, trained medical site staff will train participants and have them insert the CGM sensor 
using the supplied insertion device. Site staff must check expi[INVESTIGATOR_291576]. Participants will wear the CGM sensor for a 14-day session. At Visit 2, prior to any 
study drug injection, the system will be collected  and data transmitted. Participants will place a 
new CGM sensor at home 2 weeks prior to study Visits 3 (Week 4) and 5 (Week 12). The CGM 
sensors will be collected and da ta downloaded at Visits 3 and 5. 
Site personnel will dispense CGM supplies and initiate blinded CGM sessions at the times 
specified according to the SoA. Participants will be trained on the CGM sensor and insertion device before use and will be required to rep lace the sensor at designated intervals per the 
investigator instruction. 
The participant will be instructed to monit or fasting blood glucose and blood glucose during 
hypoglycemia by [CONTACT_291603]. 
Continuous blood glucose monitoring system compliance assessment 
At the end of each CGM session, participants wi ll return the CGM sensor(s) to the site. Site 
personnel will upload the CGM data to a vendor -hosted online portal to view data capture 
compliance using the available reports and visual ization tools. The compliance threshold of 70% 
(at least 10 days of the 14-day session) for each session is defined as the percentage of actual 
data versus expected data collected during a se ssion. Site personnel will re-educate participants 
on CGM operation and requirements when session compliance is <80%. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
45 To minimize data loss, the CGM service vendor will  review site uploads and notify site users 
and/or site monitor when sessions do not meet the compliance thresholds.  
As noted in the SoA, if a participant does not have a compliant CGM se ssion at Visit 3, the CGM 
sensor should be inserted during the study visit with re-education of the participant to ensure 
proper collection of this session and the subse quent CGM session prior to 12 weeks. This 
replacement session is not a protocol deviation,  but the updated start date/time and respective 
study week should be documented in the CRF. The replacement CGM session data must be 
collected, uploaded, and assessed for complian ce no later than the next study visit. A 
replacement CGM session is not available at Visit [ADDRESS_355845] questions or complaints regarding the CGM sensor or insertion device. 
8.2. Safety Assessments 
Planned time points for all safety assessments are provided in the SoA (Section 1.3). 
8.2.1. Physical Examinations 
A complete physical examination will include, at a minimum, assessments of 
 skin 
 CV 
 Respi[INVESTIGATOR_2133] 
 GI tract 
 neurological systems 
 thyroid, and 
 feet, including evaluation for diabetic neuropathy. 
The examination excludes pelvic, rectal, and breast examinations, unless clinically 
indicated. 
Physical examinations during in-clinic visits will be performed by a physician or other qualified 
healthcare professional. 
Height, weight, and waist circumference w ill be measured and recorded, per Appendix 7, 
Section 10.7. Investigators should pay special attention to clinical signs related to 
previous serious illnesses. 
$SSURYHGRQ$XJ*[ADDRESS_355846] of care by a 
physician or other qualified healthcare professional. 
8.2.2. Vital Signs 
For each participant, vital signs measuremen ts should be conducted according to the SoA 
(Section 1.3) and following the study-specific re commendations mentioned in Appendix 
7, Section 10.7. 
Vital signs including pulse rate (beats per minute) and blood pressure (mm Hg) will be measured 
after participant has been sitting for at least 5 minutes and before obtaining an ECG tracing and before collection of blood samples for labor atory testing, at visits where required. 
8.2.3. Electrocardiograms 
A 12-lead ECG will be obtained as outlined in the SoA (see Section 1.3) using an ECG 
machine that preferably automatically calculates the heart rate and measures PR, QRS, 
QT, and QTc intervals. 
The ECGs must be interpreted by [CONTACT_291604], and ideally while the participant is still present, for 
immediate participant management, if needed. The investigator or designee must document their 
review of the ECG. If a clinically re 5.?*7=*+78;6*52=B2<8+<.;?.-87=1.9*;=2,29*7=L<
then the investigator should assess the participant for symptoms, such as palpi[INVESTIGATOR_814], near syncope, syncope, or chest pain. 
The original ECG must be retained at the investigative site. The investigator or qualified 
-.<207..L<27=.;9;.=*=287@2559;.?*25/8;266.-2*=.9*;=2,29*7 =6*7*0.6.7=9>;98<.<  
8.2.4. Dilated Fundoscopic Examination 
A dilated retinal fundoscopic examination will be pe rformed by a qualified eye care professional 
(ophthalmologist or optometrist) for all particip ants between Visit [ADDRESS_355847] ace the study examination; results 
should be similarly recorded. 
A follow-up dilated fundoscopic examination s hould be performed by a qualified eye care 
professional (ophthalmologist or optometrist) when clinically indicated by [CONTACT_10944], and the findings should be recorded on the retinopathy eCRF. 
8.2.5. Clinical Safety Laboratory Tests 
See Section 10.2, Appendix [ADDRESS_355848] of Clinical Laboratory Tests to be performed and the 
SoA (Section 1.3) for the timing and frequency. 
The investigator must review the laboratory results, document this review, and report any 
clinically relevant changes occurring during the study as an AE. 
$SSURYHGRQ$XJ*[ADDRESS_355849] be retained with source documents unless a Source Document 
Agreement or comparable document cites an e lectronic location that accommodates the expected 
retention duration. 
5272,*55B<2072/2,*7=*+78;6*55*+8;*=8;B/27-270<*;.=18<.@ 12,1*;.78=*<<8,2*=.-@2=1=1.
>7-.;5B270-2<.*<.>75.<<3>-0.-+B=1.27?.<=20*=8;=8+.68; .<.?.;.=1*7.A9.,=.-/8;=1.
9*;=2,29*7=<,87-2=287  
All laboratory tests with values considered clinically significantly abnormal during participation 
in the study should be repeated until the values return to normal or baseline or are no longer 
considered clinically significant by [CONTACT_10982]. 
 If such values do not return to normal or baseline within a period of time judged 
reasonable by [CONTACT_093], the etiology should be identified, and the sponsor notified. 
 All protocol-required laboratory assessments, as defined in Section 10.2,  Appendix 2, 
must be conducted in accordance with the SoA (Section 1.3), standard collection 
requirements, and laboratory manual. 
If laboratory values from non-protocol-specified laboratory assessments performed at an 
investigator-designated local laboratory require a change in participant management or are 
considered clinically significant by [CONTACT_093], for example, SAE or AE or dose modification, then report the information as an AE. 
8.2.6. Pregnancy Testing 
Pregnancy testing will occur as outlined in the SoA (Section 1.3). 
Serum pregnancy test must be performed only for  WOCBP and females with a history of tubal 
ligation. 
A local urine pregnancy test must be performed for WOCBP only, prior to administering study 
intervention and the result must be  available prior to first dose or injection of study intervention 
(s). 
Additional pregnancy tests, beyond those required per the SoA, should be performed at any time 
during the study if a menstrual period is missed, there is clinical suspi[INVESTIGATOR_51940], or as required by [CONTACT_51967]. If the par ticipant is pregnant, she must be permanently 
discontinued from study intervention and the study (Sections 7 and  8.3.2). 
8.2.7. Hepatic Monitoring 
Close hepatic monitoring 
Initiating laboratory and clinical monitoring for abnormal liver laboratory test results 
Laboratory tests, including ALT, AST, ALP, TBL, direct bilirubin, GGT, and creatine kinase, 
should be repeated within [ADDRESS_355850] is needed. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
48 If a participant with baseline results of...  develops the following elevations  
ALT or AST <1.5x ULN &8;%&G
A'!  
ALP <1.5x ULN #GA'!  
TBL <1.5x ULN &GA'!.A,.9=/8;9*;=2,29 *7=<@2=125+.;=L<<B7-;86.  
&8;%&GA'!  &8;%&GA+*<.527.  
#GA'!  #GA+*<.527.  
&GA'!  &GA+*<.527..A,.9=/8 ;9*;=2,29*7=<@2=125+.;=L<
syndrome) 
Abbreviations: ALP = alkaline phosphatase; ALT = alanine am inotransferase; AST = aspartate aminotransferase; 
TBL = total bilirubin level; ULN = upper limit of normal. 
	
	






  
/=1.*+78;6*552?.;=.<=;.<>5=9.;<2<=<8;@8;<.7<,5272,*5 *7-5*+8;*=8;B6872=8;270*7-
.?*5>*=287/8;98<<2+5.,*><.<8/*+78;6*552?.;=.<=<<18>5-+ .272=2*=.-+B=1.27?.<=20*=8;27
,87<>5=*=287@2=1=1.6.-2,*56872=8;=*[ZIP_CODE]>6=12<.?*5> *=287<18>5-27,5>-.91B<2,*5
.A*627*=287*7-*=18;8>016.-2,*512<=8;B27,5>-270  
 <B69=86<  
 ;.,.7=2557.<<.</8;.A*695.1.*;=/*25>;.<B<=.62,27/.,=28 71B98=.7<2878;<.2C>;.<  
 ;.,.7==;*?.5  
 12<=8;B8/,87,862=*7=6.-2,*=2 87<27,5>-2708?.;=1.,8>7=.;1.;+*5*7--2.=*;B
<>995.6.7=<*7-  
 12<=8;B8/*5,8185-;274270*7-8=1.;<>+<=*7,.*+><.  
Frequency of monitoring 
72=2*55B6872=8;2708/<B69=86< *7-1.9*=2,+28,1.62,*5=.<=<<18>5-+.-87.*=*/;.:>.7,B8/
=8
=26.<@..45B+*<.-87=1.9*;=2,29*7=L<,5272,*5,87-2= 287*7-1.9*=2,+28,1.62,*5=.<=<  
%>+<.:>.7=5B=1./;.:>.7,B8/6872=8;2706*B+.58@.;.-=887, ..?.;B=8@..4<2/=1.
9*;=2,29*7=L<,5272,*5,87-2= 287*7-5*+;.<>5=<<=*+252C.  
 872=8;2708/&%&#*7-&<18>5-,87=27>.>7=255.?. 5<78;6*52C.8;;.=>;7=8
*99;8A26*=.+*<.527.5.?.5<  
Special care should be taken to minimize the volume of blood taken during hepatic monitoring. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
49 
  
	
	



  
A comprehensive evaluation should be performed to search for possible causes of liver injury if 
1 or more of the conditions in this table occur. 
If a participant with baseline 
results of...  develops the following elevations  
ALT or AST <1.5x ULN &8;%&G
A'!@2=11.9*=2,<207<8;<B69=86<a, or 
&8;%&GA'!  
ALP <1.5x ULN #G
A'!  
TBL <1.5x ULN &GA'!.A,.9=/8;9*;=2,29 *7=<@2=125+.;=L<<B7-;86.  
&8;%&GA'!  &8;%&GA+*<.527.@2=11.9*=2,<207<8;<B69=86<a, or 
&8;%&G
A+*<.527.  
#GA'!  #GA+*<.527.  
&GA'!  &GA+*<.527..A,.9=/8;9*;=2,29*7=<@2=125+.;=L<<B7-;8 6. 
Abbreviations: ALP = alkaline phosphatase; ALT = alanine am inotransferase; AST = aspartate aminotransferase; 
TBL = total bilirubin level; ULN = upper limit of normal. 
a Hepatic signs or symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, 
rash, and/or eosinophilia >5%. 
		

 

	

  
=*[ZIP_CODE]>6=12<.?*5>*=287<18>5-27,5>-. 
 91B<2,*5.A*627*=287*7-*=18;8>016.-2,*512<=8;B*<8>=527. -*+8?.  
 =.<=</8;  
o #&!$  
o ?2;*51.9*=2=2<8;*7-  
o *>=8266>7.1.9*=2=2<*7-  
 *7*+-8627*526*0270<=>-B/8;.A*695.>5=;*<8>7-8;,869>=.- =8680;*91B<,*7  
*<.-87=1.9*;=2,29*7=L<12<=8;B*7-272=2*5;.<>5=</>;=1.; =.<=270<18>5-+.,87<2-.;.-27
,87<>5=*=287@2=1=1.6.-2,*56872=8;27,5>-270=.<=</8;  
 1.9*=2=2<?2;><  
 ,B=86.0*58?2;><  
 9<=.27*;;?2;><  
 *,.=*627891.75.?.5<  
 *,.=*627891.79;8=.27*-->,=<  
 >;27.=8A2,8580B<,;..7  
 )25<87L<-2<.*<.  
 +588-*5,81855.?.5<  
 >;27*;B.=1B505>,>;872-.*7-  
 +588-918<91*=2-B5.=1*785  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
50 *<.-87=1.,2;,>6<=*7,.<*7-=1.27?.<=20*=8;L<*<<.<<6.7=8/ =1.9*;=2,29*7=L<,5272,*5
,87-2=287=1.27?.<=20*=8;<18>5-,87<2-.;;./.;;270=1.9*;=2 ,29*7=/8;*1.9*=[ZIP_CODE]<=8;
0*<=;8.7=.;[ZIP_CODE]<=,87<>5=*=2876*07.=2,;.<87*7,.,185*[ZIP_CODE]* 7,;.*=80;*91B.7-8<,892,
;.=;80;*-.,185*[ZIP_CODE]*7,;.*=80;*91B,*;-2*,.,18,*;-280;*68; *52?.;+289<B  
Additional hepatic data collection (hepatic safe ty CRF) in study participants who have 
abnormal liver tests during the study 
Collect additional hepatic safety data collection in the hepatic safety CRFs if a participant 
develops 
 a hepatic event considered to be an SAE 
 discontinues study intervention due to a hepatic event, or 
 has changes in laboratory results described in this table. 
If a participant with 
baseline results of...  
	



    
ALT <1.5x ULN &=8GA'!878;68;.
consecutive blood tests 
Collect additional hepatic safety data in 
the hepatic safety CRF. &GA'!  &G
A+*<.527.878;68;.
consecutive blood tests 
TBL <1.5x ULN &GA'!.A,.9=/8;9*;=2,29*7=<
@2=125+.;=L<<B7-;86.  
&GA'!  &GA+*<.527.  
ALP <1.5x ULN #GA'!878;68;.,87<.,>=2?.
blood tests 
#GA ULN #=8GA+*<.527.878;68;.
consecutive blood tests 
Abbreviations: ALP = alkaline phosphatase; ALT = alanine am inotransferase; AST = aspartate aminotransferase; 
CRF = case report form; TBL = total bilirub in level; ULN = upper limit of normal. 
Note: The interval between the [ADDRESS_355851] Complaints 
The definitions of the following events can be found in Section 10.3, Appendix 3: 
 AEs 
 SAEs, and 
 PCs. 
These events will be reported by [CONTACT_2299],  or, when appropriate, by a caregiver, surrogate, 
8;=1.9*;=2,29*7=L<5.0*55B*>=18;2C.-;.9;.<.7=*=2?.  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet these definitions and remain responsible for following up events that 
are serious, considered related to the study intervention or study procedures, or that caused the 
participant to discontinue the study intervention or study (see Section 7). 
$SSURYHGRQ$XJ*[ADDRESS_355852] to follow-up (as defined in Section 7.3). 
For PCs, the investigator is responsible for ensuring that follow-up includes any supplemental 
investigations as indicated to elucidate the nature and/or causality. Further information on 
follow-up procedures is provided in Section 10.3, Appendix 3. 
8.3.1. Timing and Mechanism for Collecting Events 
This table describes the timing, deadline s, and mechanism for collecting events. 
Event  Collection 
Start  Collection Stop Timing for 
Reporting to Sponsor
 or 
Designee  Mechanism 
for Reporting Back -Up 
Method 
of Reporting 
Adverse Event 
AE Signing of 
the ICF  Participation in 
study has ended As soon as 
possible upon site awareness AE CRF  N/A 
Serious Adverse Event 
SAE and SAE updates H 
prior to start of study 
intervention and deemed 
reasonably possibly related 
to study procedures  Signing of 
the ICF  Start of 
intervention  Within 24 h 
of awareness SAE CRF SAE paper 
form  
SAE and SAE updates H 
after start of study 
intervention  Start of 
intervention  Participation in 
study has ended  Within 24 h 
of awareness SAE CRF SAE paper 
form  
SAEa H */=.;9*;=2,29*7=L<
study participation has ended 
and the investigator 
becomes aware  After 
9*;=2,29*7=L<
study participation has ended N/A Promptly  SAE paper 
form  N/A 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
52 Event  Collection 
Start  Collection Stop Timing for 
Reporting to 
Sponsor  or 
Designee  Mechanism 
for Reporting Back -Up 
Method 
of 
Reporting 
Pregnancy 
Pregnancy in female 
participants and female 
partners of male participants After the 
start of 
study intervention Participation in 
study has ended  Within 24 h 
(see Section 
8.3.2 ) Pregnancy 
paper form Pregnancy 
paper 
form  
Product Complaints 
PC associated with an SAE 
or might have led to an SAE Start of 
study intervention End of study 
intervention  Within [ADDRESS_355853] 
Complaint F
orm N/A 
PC not associated with an 
SAE  Start of 
study 
intervention End of study 
intervention  Within [ADDRESS_355854] 
Complaint 
Form N/A 
Updated PC information  I I As soon as 
possible upon 
site 
awareness Originally 
completed 
Product 
Complaint 
form  with all 
changes 
signed and 
dated by [CONTACT_1275] N/A 
PC (if investigator becomes 
aware)  Participation 
in study has ended
 N/A Promptly  Product 
Complaint form
  
Abbreviations: AE = adverse event; CRF = case report form ; ICF = informed consent form; PC = product complaint; 
SAE = serious adverse event.  
a Serious adverse events should not be reported unless the investigator deems them to be possibly related to study treatment or 
study participation. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
53 8.3.2. Pregnancy 
Collection of pregnancy information 
Male participants with partners who become pregnant 
&1.27?.<=20*=8;@255*==.69==8,855.,=9;.07*7,B27/8;6*=287 87*7B6*5.9*;=2,29*7=L</.6*5.
partner who becomes pregnant while the male partic ipant is in this study. This applies only to 
male participants who receive study intervention. After learning of a pregnancy in the female partner of a study participant, the investigator 
 will obtain a consent to release information from the pregnant female partner 
directly, and 
 within [ADDRESS_355855] pregnancy information 
on the appropriate form and submit it to the sponsor. 
The female partner will also be followed to determine the outcome of the pregnancy. Information on the status of the mother and child will be forwarded to the sponsor. Generally, the follow-up 
will be no longer than 6 to 8 weeks following the estimated delivery date. Any termination of the pregnancy will be reported regardless of ges tational age, fetal status (presence or absence of 
anomalies), or indication for the procedure. 
Female participants who become pregnant 
The investigator will collect pregnancy information on any female participant who becomes 
pregnant while participating in this study. The initial information will be recorded on the 
*99;89;2*=./8;6*7-<>+62==.-=8=1.<987<8;@2=12718>;<8 /5.*;72708/*9*;=2,29*7=L<
pregnancy. 
The participant will be followed to determine the outcome of the pregnancy. The investigator 
will collect follow-up information on the particip ant and the neonate, and the information will be 
forwarded to the sponsor. Generally, follow-up will not be required for longer than 6 to 8 weeks 
beyond the estimated delivery date. Any terminati on of pregnancy will be reported, regardless of 
gestational age,  fetal status (presence or absence of anomalies), or indication for the procedure. 
While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be reported as an AE or SAE. 
A spontaneous abortion, occurring at <[ADDRESS_355856] 
discontinuation process and continue directly  to the follow-up phase. The follow-up on the 
pregnancy outcome should continue independent  of intervention or study discontinuation. 
$SSURYHGRQ$XJ*[ADDRESS_355857] 
[IP_ADDRESS]. Gastrointestinal Adverse Event 
Tirzepatide may cause severe GI AEs, such as nausea, vomiting, and diarrhea. Information about 
severe GI AEs as well as an ti-emetic/anti-diarrheal use will be collected in the CRF/AE form. 
For detailed information concerning the management of GI AEs, refer to Section 6.5.1. 
[IP_ADDRESS]. Dehydration 
Severe gastrointestinal events may lead to de hydration and volume depletion, which can cause a 
deterioration in renal function, including acute rena l failure. Participants should be advised of the 
potential risk of dehydration, particularly in relation to gastrointestinal adverse reactions or other 
AEs and take precautions to avoid fluid depletion. 
[IP_ADDRESS]. Renal Safety 
Renal safety will be assessed based on rep eated renal functional assessment as well as 
assessment of AEs suggestive of acute or worsening of chronic renal disease. 
[IP_ADDRESS]. Exocrine Pancreas Safety 
Diagnosis of acute pancreatitis 
Acute pancreatitis is an AE of special interest in al l studies with tirzepatide, including this study. 
The diagnosis of acute pancreatitis requires 2 of the following 3 features (Banks et al. 2006; 
Koizumi 2006): 
 abdominal pain, characteristic of acute pancreatitis, that is, epi[INVESTIGATOR_291577], often associated with nausea and vomiting 
 <.;>6*6B5*<.=8=*59*7,;.*=2,8;+8=1*7-	8;529*<.G
 x ULN, or 
 characteristic findings of acute pancreatitis on CT scan or MRI. 
If acute pancreatitis is suspected, the investigator should 
 obtain appropriate laboratory tests, including pa ncreatic amylase and lipase, via a local 
laboratory  
 perform imaging studies, such as abdominal CT scan with or without contrast, MRI, or gallbladder ultrasound. 
Discontinuation and rescue interv ention for acute pancreatitis  
If laboratory values and/or abdominal imaging support the diagnosis of acute pancreatitis, the 
participant must discontinue therapy with inve stigational product(s) but will continue in the 
study on another glucose-lowering regimen; details  on rescue intervention will be provided. The 
most appropriate diabetes therapeutic regimen will be decided by [CONTACT_093], based on the 9*;=2,29*7=L<,5272,*5<=*=>< ;.?2.@8/=1.9*;=2,29*7=L<,8 7,862=*7=6.-2,*=287<<18>5-+.
conducted to assess any potential causal relationship with pancreatitis. 
$SSURYHGRQ$XJ*[ADDRESS_355858] report the event as an SAE if the typi[INVESTIGATOR_10926]/or symptoms of 
pancreatitis are present and are confirmed by 
 laboratory values (lipase or amylase [total and/or pancreatic]), and 
 imaging studies. 
If a potential event does not meet all of these criteria, the investigator will decide the seriousness of the event, either AE or SAE. 
&1.27?.<=20*=8;@255*5<8;.?2.@=1.9*;=2,29*7=L<,87,862=*7=6.-2,*=287<=8*<<.<<*7B
potential causal relationship with pancreatitis and will report the relatedness of study 
intervention(s) to the event. 
[IP_ADDRESS]. Thyroid C-Cell Hyperplasia and C-Cell Neoplasms 
Individuals with personal or family history of MTC and/or MEN2 will be excluded from the 
study. 
[IP_ADDRESS]. Hypoglycemia 
Participants will be trained by [CONTACT_291605], how to treat hypoglycemia, and how to collect appropriate information for each epi[INVESTIGATOR_291578] (Section 1.3). Site personnel will 
enter this information into the eCRF at each visit. 
&8*?82-->952,*=.;.98;=270*55,87<.,>=2?.?*5>.<F
  mg/dL (3.9 mmol/L) occurring 
within 1-hour period may be considered to be a single hypoglycemic event (Weinberg et al. 
2010; Danne et al. 2013). 
CGM data will not be used to evaluate hypoglycemia. 
Hypoglycemia classification and definitions 
Level 1  
Glucose <70 mg/dL (<3.9 6685	*7-G 60	-G

  mmol/L) 
Level [ADDRESS_355859]-acting 
carbohydrates. Providers should continue to counsel participants to treat hypoglycemia at this 
glucose alert value. 
Level 2  
Glucose <54 mg/dL (<3.0 mmol/L) 
Level 2 hypoglycemia is also referred to as documented or blood glucose-confirmed 
hypoglycemia with glucose <54 mg/dL (<3.0 mmol/L). This glucose threshold is clinically relevant regardless of the presence or absence of symptoms of hypoglycemia. 
$SSURYHGRQ$XJ*[ADDRESS_355860] required assistance and is not predicated on the report 
of a participant simply having received assistance. 
Examples of severe hypoglycemia in adults are 
 altered mental status and the inability to assist in their own care 
 semiconscious or unconscious, or 
 coma with or without seizures. 
Glucose measurements may not be available during such an event, but neurological recovery 
attributable to the restoration of glucose concentration to normal is considered sufficient evidence that the event was induced by a low glucose concentration. 
Nocturnal hypoglycemia
 
Nocturnal hypoglycemia is  a hypoglycemia event, including severe hypoglycemia, which occurs 
at night  and presumably during sleep. 
Reporting of severe hypoglycemic events 
If a hypoglycemic event meets the criteria of severe, the investigator must record the event as 
serious on the AE CRF and report it to Lilly as an SAE. 
The investigator should also determine if repe ated or prolonged epi[INVESTIGATOR_291579]. 
[IP_ADDRESS]. Severe, Persistent Hyperglycemia 
Severe, persistent hyperglycemia will be assessed during the study to determine the risk of 
extreme imbalance in glycemic control. 
Severe, persistent hyperglycemia is defined as an FBG (via SMBG) >270 mg/dL (>15 mmol/L) 
during the first 4 weeks or >240 mg/dL (>13.3 mmol/L) from Weeks 5-[ADDRESS_355861] 2 consecutive weeks. No rescue therapy should be used, see section 6.1.2. 
[IP_ADDRESS]. Hypersensitivity Reactions 
Many drugs, particularly oral agents and biologic agents, carry the risk of systemic hypersensitivity reactions. If such a reaction occurs, additional data should be provided to the sponsor in the designated CRFs. 
Sites should have appropriately trained medical staff and appropriate medical equipment 
available when study participants are receiving study intervention. It is recommended that 
participants who experience a systemic hypersensi tivity reaction be treated per national and 
international guidelines. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
57 In the case of a suspected hypersensitivity event, additional blood samples should be collected as 
described in Appendix 2, Section 10.2.1. Laboratory results are provided to the sponsor via the 
central laboratory. 
If the investigator determines that a systemic hypersensitivity reaction has occurred related to 
study intervention administration, the participan t may be permanently discontinued from the 
27=.;?.7=287*7-=1.<987<8;L<-.<207*= ed medical monitor should be notified. If the investigator 
is uncertain about whether a systemic hypersensitivity reaction has occurred and whether 
discontinuation of study intervention is warran ted, the investigator may consult the sponsor. 
[IP_ADDRESS]. Injection-Site Reactions 
Symptoms and signs of a local ISR may include erythema, induration, pain, pruritus, and edema. 
If an ISR is reported by a participant or study personnel, the ISR CRF will be used to capture 
additional information about this reaction, for exampl e, injection-site pain, degree and area of 
erythema, induration, pruritis, and edema. 
At the time of AE occurrence in the tirzepatide group, samples will  be collected for measurement 
of tirzepatide anti-drug antibodies and tirzepatide concentration. 
[IP_ADDRESS]. Diabetic Retinopathy Complications 
Dilated retinal fundoscopic examination for all partic ipants will be performed by a qualified eye 
care professional (ophthalmologist or optometrist) between Visit [ADDRESS_355862] be recorded on the 
retinopathy CRF. 
[IP_ADDRESS]. Hepatobiliary Disorders 
All events of treatment-emergent biliary colic, cholecystitis, or other suspected events related to 
gallbladder disease should be evaluated and additional diagnostic tests performed, as needed. In 
cases of elevated liver markers, hepatic monitoring should be initiated as outlined in Section 8.2.7. 
8.4. Pharmacokinetics 
Pharmacokinetic parameters are not evaluated in this study. 
8.5. Pharmacodynamics 
Samples to assess the PD propertie s of tirzepatide are included in the efficacy measures and not 
applicable in this section. 
8.6. Genetics 
Genetics are not evaluated in this study. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
58 8.7. Biomarkers 
Biomarkers are not evaluated in this study. 
8.8. Immunogenicity Assessments 
Immunogenicity will not be proactively assessed in this study. 
In the case of hypersensitivity or ISR, samples will be collected if needed as described in 
Section 10.2.1. 
8.9. Health Economics 
Health economics parameters are not evaluated in this study. 
$SSURYHGRQ$XJ*[ADDRESS_355863] visit, 
and it will include a more technical and detailed description of the statistical analyses described 
in this section. 
9.1. Statistical Hypotheses 
The null hypothesis corresponding to the primary objective of this study is as follows: 
 P H1,0: Mean change from baseline in HbA1c is greater than or equal to zero at Week 12 in 
tirzepatide 5 mg arm. 
Operationally the hypotheses will be evaluated by 2-sided tests. 
9.2. Analyses Sets 
This table defines the analysis population and datasets for the purposes of analysis based on the 
estimands defined in Section 3. 
9.3. Statistical Analyses 
9.3.1. General Considerations 
Statistical analysis of this study will be the responsibility of Lilly or its designee. 
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol. Any other change to the data analysis 
methods described in the protocol, and the justificat ion for making the change, will be described 
in the statistical analysis plan or clinical study report. Additional exploratory analyses of the data 
will be conducted as deemed appropriate. 
All tests of treatment effects will be conducted at a 2-sided alpha level of 0.05/1-sided alpha 
level of 0.025, unless otherwise stated, and all confidence intervals will be given at a 2-sided 
95% level.  
Baseline is defined as the last non-missing measurement recorded on or before the treatment initiation visit, prior to first dose of treatment, unless otherwise specified. 
Analyses will use the EAS population set to evaluate the efficacy estimand. Population/Analysis Set Description 
Screened population All participants who signed informed consent 
Modified intent-to-treat population (mITT) All participants who are expos ed to at least 1 dose of study 
intervention.  
Efficacy Analysis Set (EAS): This analysis set will 
be used to estimate the efficacy estimand for the 
primary objective  Data obtained during the treatment period from the mITT 
population excluding participants who were inadvertently 
enrolled, excluding data after permanent discontinuation of 
treatment or initiation of prohibited medication 
Safety Analysis Set (SS): This analysis will be used 
to assess the safety of study treatment  Data obtained during the Treatment Period from the mITT 
population, regardless of adherence to treatment or 
initiation of prohibited medication 
$SSURYHGRQ$XJ*[ADDRESS_355864] deviation, 
median, minimum, and maximum. The analysis model to make comparisons within treatment 
relative to continuous measurements assessed over time will be an MMRM with terms for: 
 visit 
 country 
 b*<.527.+,F

 , and 
 baseline measurement as a covariate. 
For analyses of HbA1c, continuous baseline Hb A1c will be included in the model instead of 
baseline HbA1c category. An unstructured cova riance structure will model the relationship of 
within-participant errors. 
Summary statistics for categorical  measures, including categorized continuous measures, will 
include sample size, frequency, and percentages. Logistic regression may be used to examine the 
treatment effect from baseline at [ADDRESS_355865] of discrete count measures 
if deemed appropriate. 
Adjustments to the planned analyses are describe d in the final clinical study report or in the SAP. 
9.3.2. Primary Endpoint Analysis 
The primary endpoint for this study is change from  baseline in HbA1c at Week 12. This endpoint 
will be used to evaluate the primary objective of the study (Section 3). 
The null hypothesis corresponding to the primary objective is specified in Section 9.1. 
The primary objective based on the efficacy estimand defined in Section 3 will be evaluated 
using the EAS dataset (Section 9.2). The primary analysis model for HbA1c measurements over 
time will be an MMRM. The response variable of MMRM will be change in HbA1c values from 
baseline obtained at each scheduled postbaseline visit. The independent variables of the MMRM 
model are visit, and country as fixed effects and baseline HbA1c as covariates. Missing data will 
be addressed by [CONTACT_56412]. No explicit  imputation methods for missing data will be 
employed. The P values obtained for the least square means for change from baseline will be 
used to determine the statistical signif icance to achieve the primary objective. 
9.3.3. Secondary Endpoints Analysis 
Endpoints for secondary objectives are described in Section 3 and will be evaluated based on the 
efficacy estimand. Additional details will be provided in the SAP. 
9.3.4. Exploratory Endpoints Analysis 
Endpoints for exploratory objecti ves are described in Section 3 and will be evaluated based on 
the efficacy estimand. Additional details will be provided in the SAP. 
9.3.5. Safety Analyses 
Safety assessments will be done using the Safety Analysis Set (see Section 9.1) irrespective of 
adherence to study intervention or initiation of prohibited medication, unless indicated otherwise. 
$SSURYHGRQ$XJ*[ADDRESS_355866] dose 
through end of study. Counts and proportions of par ticipants experiencing AEs will be reported. 
[IP_ADDRESS]. Hypoglycemic Events 
Incidence of documented symptomatic hypoglycemia events and severe hypoglycemia will be summarized. Rate of hypoglycemic epi[INVESTIGATOR_126150] a generalized linear mixed-
effects model assuming negative binomial dist ribution for hypoglycemic epi[INVESTIGATOR_291580]. 
[IP_ADDRESS]. Gastrointestinal Events 
Summaries and analyses for incidence and severi ty of nausea, vomiting, and diarrhea will be 
provided. 
[IP_ADDRESS]. Central Laboratory Measures and Vital Signs 
Values and changes from baseline to postbas eline values of appropriate central laboratory 
measures and vital signs will be sum marized at each scheduled visit. 
The analysis model to make comparisons within  treatment relative to continuous change from 
baseline values assesse d over time will be an MMRM, with terms: visit, country, and baseline 
measurement as covariates. 
An unstructured covariance structure will m odel relationship of within-participant errors. 
The percentages of participants with treatment-emergent abnormal, high, or low laboratory 
measures at any time will be summarized. 
A treatment-emergent abnormal value is defined as a change from normal value at baseline to an 
abnormal value at any time during the follow-up. 
A treatment-emergent high result is defined as a change from a value less than or equal to the 
high limit at baseline to a value greater than the high limit at any time during the Treatment and Follow-Up periods. 
A treatment-emergent low result is defined as a change from a value greater than or equal to the 
low limit at baseline to a value less than th e low limit at any time during the Treatment and 
Follow-Up periods. 
High and low limits will be provided in SAP. 
9.3.6. Subgroup Analyses 
Subgroup analyses of the primary and secondary e ndpoint will be made to assess consistency of 
the improvement from baseline across the following subgroups 
 Age group: < 65 B.*;<?<G 65 years 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
62  Sex: female vs male 
 Race: white vs black vs other  
 Ethnicity: Hispanic vs not Hispanic  
 Baseline GLP-1 RA: liraglutide vs semaglutide vs dulaglutide 
 Baseline GLP-1 RA equivalent doses (adapted from Almandoz et al. 2020):  
o dulaglutide 0.75 mg and liraglutide 1.2 mg vs  
o dulaglutide 1.5 mg, semaglutide 0.5 mg, and liraglutide 1.8 mg vs  
o dulaglutide 3 mg and semaglutide 1 mg vs  
o dulaglutide 4.5 mg and semaglutide 2 mg, and 
 *<.527.+,F

 . 
9.4. Interim Analysis 
No interim analyses are planned for this study. If an unplanned interim analysis is deemed 
necessary for reasons other than a safety concern, the protocol must be amended. 
9.5. Sample Size Determination 
A sample size of [ADDRESS_355867] 90% power to show an improvement in 
HbA1c from baseline at Week 12. This sample size is using the following assumptions: 
 a 1-sample t-test with 2-sided significance level of 0.05 
 within treatment difference from baseline at Week 12 is 0.3%, and 
 intra-subject variability of 1.1%. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
63 10. Supporting Documentation and Operational Considerations 
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations 
10.1.1. Regulatory and Ethical Considerations 
This study will be conducted in accordance with the protocol and with the following: 
O consensus ethical principles derived f rom international guidelines, including 
the Declaration of Helsinki and Counc il for International Organizations of 
Medical Sciences (CIOMS) International Ethical Guidelines 
O applicable ICH Good Clinical Practice Guidelines 
o International Organization for Standardization (ISO) [ZIP_CODE], and 
O applicable laws and regulations. 
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
documents, for example, advertisements, must be submitted to an IRB/IEC by [CONTACT_22843]/IEC before the study is initiated. 
Any amendments to the protocol will requi re IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an 
immediate hazard to study participants. 
Protocols and any substantial amendments to the protocol will require health authority 
approval prior to initiation except for chan ges necessary to eliminate an immediate 
hazard to study participants. 
The investigator will be responsible for the following: 
O Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, and 
procedures established by [CONTACT_1201]/IEC 
O Notifying the IRB/IEC of SAEs or other significant safety findings as required 
by [CONTACT_1744]/IEC procedures 
O Providing oversight of study conduct for participants under their responsibility 
and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, 
European regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations, and 
o Reporting to the sponsor or designee signific ant issues related to participant safety, 
participant rights, or data integrity. 
Investigator sites are compensated for participation in the study as detailed in the Clinical Trial Agreement. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
64 10.1.2. Financial Disclosure 
Investigators and sub-investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are responsible for providing information on financial in terests during the course of the study and for 
1 year after completion of the study. 
10.1.3. Informed Consent Process 
&1.27?.<=20*=8;8;=1.27?.<=20*=8;L<;.9;.<.7=*=2?.@255.A95 *27=1.7*=>;.[ADDRESS_355868] be informed that their participation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local 
regulations, ICH guidelines, privacy, and data protection requirements, where applicable, and the 
IRB/IEC or study center. 
The medical record must include a statement that written informed consent was obtained before 
the participant was entered in the study and the date the written consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF. 
Participants must be reconsented to the most current version of the ICF(s) during their 
participation in the study. 
A copy of the ICF(s) must be provided to the participant and is kept on file. 
Participants who are rescreened are required to sign a new ICF. 
10.1.4. Data Protection 
Participants will be assigned a unique identifier by [CONTACT_456]. Any participant records, datasets, 
or tissue samples that are transferred to the sponsor will contain the identifier only; participant 
names or any information which would make the par ticipant identifiable will not be transferred. 
&1.9*;=2,29*7=6><=+.27/8;6.-= 1*==1.9*;=2,29*7=L<9.;<87* 5<=>-B -related data will be used 
by [CONTACT_10999]. The level of disclosure must also be explained to the participant who will be required to give consent for their data to be used as described in the informed consent. 
The participant must be informed that their medical records may be examined by [CONTACT_11000], by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668]. 
The sponsor has processes in place to ensure data protection, information security, and data 
integrity. These processes include appropriate contingency plan(s) for appropriate and timely 
response in the event of a data security breach. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
65 10.1.5. Committees Structure 
[IP_ADDRESS]. Internal Assessment Committee 
Not applicable. 
[IP_ADDRESS]. External Clinical Endpoint Committee 
Not applicable.  
10.1.6. Dissemination of Clinical Study Data 
Reports 
The sponsor will disclose a summary of study information, including tabular study results, on 
publicly available websites where required by [CONTACT_51967]. 
The summary of results will be posted within th e time frame specified by [CONTACT_51967]. 
If the study remains ongoing in some countries and a statistical analysis of an incomplete dataset 
would result in analyses lacking scientific rigor (for example, underpowered) or compromise the 
integrity of the overall analyses (for example, study not yet unblinded), the summary of results 
will be submitted within 1 year after the end of the study globally or as soon as available, whichever is earlier. 
Data 
The sponsor provides access to all individual par ticipant data collected during the study, after 
anonymization, with the exception of pharm *,8427.=2,8;0.7.=2,-*=*R  
Data are available to request 6 months after the indication studied has been approved in the US 
*7-'*7-*/=.;9;26*;B9>+52,*=287*,,.9=*7,.@12,1.?.;2<5 *=.;R!8.A92;*=287-*=.8/-*=*
requests is currently set once data are made available. 
Access is provided after a proposal has been ap proved by [CONTACT_291606] a signed data-sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, 
and blank or annotated case report forms, will  be provided in a secure data-sharing environment 
for up to [ADDRESS_355869] maintain accurate documentation (source data) that supports the 
information entered in the CRF. 
$SSURYHGRQ$XJ*[ADDRESS_355870] permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source documents. 
Quality tolerance limits 
Quality tolerance limits will be predefined to identify systematic issues that can impact 
participant safety and/or reliability of study results. These predefined parameters will be monitored during the study and important excurs ions from the quality tolerance limits 
and remedial actions taken will be summarized in the clinical study report. 
Data monitoring and management 
Monitoring details describing strategy (for example, risk-based initiatives in operations 
and quality, such as risk management and miti gation strategies and analytical risk-based 
monitoring), methods, responsibilities, and requirements, including handling of 
noncompliance issues and monitoring techniques are provided in the Monitoring Plan. 
The sponsor or designee is responsible for the data management of this study, including 
quality checking of the data. 
The sponsor assumes accountability for actions delegated to other individuals, for 
example, contract research organizations. 
The sponsor or designee will perform monitoring to confirm that data transcribed into the 
CRF by [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of par ticipants are being protected; and that the 
study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements. 
Records retention and audits 
Records and documents, including signed ICFs, pertaining to the conduct of this study 
must be retained by [CONTACT_291607] a longer retention 
period. No records may be destroyed during the retention period without the written approval of the sponsor. No records may be transferred to another location or party 
without written notification to the sponsor. 
In addition, sponsor or its representatives will periodically check a sample of the 
participant data recorded against source documents at the study site. The study may be audited by [CONTACT_291608], and/or regulatory agencies at any time. 
Investigators will be given notice before an audit occurs. 
Data capture system 
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported to the sponsor. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
67 Electronic data capture system 
An electronic data capture system (EDC) will be used in this study for the collection of CRF 
data. The investigator maintains a separate source for the data entered by [CONTACT_81285]-provided EDC system. The investigator is responsible for the 
identification of any data to be considered so urce and for the confirmation that data reported are 
accurate and complete by [CONTACT_11003]. 
Additionally, other data (study drug administra tion and hypoglycemia information) will be 
collected by [CONTACT_2299], via a paper sour ce document, and will be transcribed by [CONTACT_291609]. 
Data storage and access 
Data collected via the sponsor-provided data capture system(s) will be stored at third parties. 
The investigator will have continuous access to the data during the study and until 
decommissioning of the data capture system(s). Prior to decommissioning, the investigator will receive or access an archival copy of pertinent data for retention. 
Data managed by a central vendor, such as laborator y test data, will be stored electronically in 
=1.,.7=;*5?.7-8;L<-*=*+*<.<B<=.6*7- reports or electronic transfers will be provided to the 
investigator for review and retention. Data will subsequently be transferred from the central 
vendor to the sponsor data warehouse. 
Data from complaint forms submitted to the spon sor will be encoded and stored in the global 
product complaint management system. 
10.1.8. Source Documents 
Source documents provide evidence for the existence of the participant and substantiate 
=1.27=.0;2=B8/=1.-*=*,855.,=. -%8>;,.-8,>6.7=<*;./25.- *==1.27?.<=20*=8;L<<2=.  
Data reported on or entered in the CRF and are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available. 
Definition of what constitutes source data can be found in Section 10.1.7. 
10.1.9. Study and Site Start and Closure 
First act of recruitment 
The study start date is the date on which the clinical study will be open for recruitment of 
participants. 
The first act of recruitment is the /2;<=<2=.L</2;<=9*;=2,29*7=?2<2=(2<2= and will be the study 
start date. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
68 Study or site termination 
&1.<987<8;8;<987<8;L< designee reserves the right to close the study site or terminate the study 
at any time for any reason at the sole discreti on of the sponsor. Study sites will be closed upon 
study completion. A study site is considered closed when all required documents and study 
supplies have been collected and a study site closure visit has been performed. 
The investigator may initiate study site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by [CONTACT_11004]: 
 For study termination: 
o discontinuation of further study intervention development 
 For site termination: 
o failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor Ls procedures, or GCP guidelines 
o inadequate recruitment (evaluated after a reasonable amount of time) of participants by [CONTACT_093], and 
o total number of participants included earlier than expected. 
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by [CONTACT_11005]. The investigator shall promptly inform the participant and should assure 
appropriate participant therapy and/or follow-up. 
10.1.10. Publication Policy 
7*,,8;-*7,.@2=1=1.<987<8;L<9>+52,*=2879852,B , the results of this study will be submitted 
for publication by a peer-reviewed journal. 10.1.11. Investigator Information 
Researchers with appropriate education, training , and experience, as determined by [CONTACT_456], 
will participate as investigators in this clinical study. 
10.1.12. Sample Retention 
Sample retention enables use of new technologies, response to regulatory questions, and 
investigation of variable response that may not  be observed until later in the development 
8/R=2;C.9*=2-.R8;*/=.;R=2;C.9*=2-.  become(s) commercially available.
 
Sample Type  Custodian  Retention Period after Last Patient Visita  
Tirzepatide concentrationb Sponsor or designee  1 year 
Tirzepatide anti-drug antibodiesb Sponsor or designee 15 years 
a Retention periods may differ locally. 
b Sample collection only for hypersensitivity and injection-site reactions.   
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
69 10.2. Appendix 2: Clinical Laboratory Tests 
The tests detailed in the table below will be performed by [CONTACT_11008]-designated laboratory or by 
[CONTACT_291610]. 
Local laboratory results are only required in the ev ent that the central laboratory results are not 
available in time for either study interventi on administration and/or response evaluation. If a 
local sample is required, it is important that the sample for central analysis is obtained at the 
same time. Additionally, if the local laboratory results are used to make either a study intervention decision or response evaluation, the results must be recorded. 
In circumstances where the sponsor approves local laboratory testing in lieu of central laboratory 
testing (in the table below), the local laboratory must be qualified in accordance with applicable local regulations. 
Protocol-specific requirements for inclusion or exclusion of participants are detailed in Section [ADDRESS_355871] document their review of the laboratory safety results. 
  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
70 Clinical Laboratory Tests  Comments 
Hematology Assayed by [CONTACT_11007]-designated laboratory. 
Hemoglobin   
Hematocrit   
Erythrocyte count (RBCs - red blood cells)   
Mean cell volume    
Mean cell hemoglobin   
Mean cell hemoglobin concentration    
Leukocytes (WBCs - white blood cells)    
Differential   
  Neutrophils,   
  Lymphocytes   
  Monocytes   
  Eosinophils   
  Basophils   
Platelets   
Cell morphology (RBCs and WBCs) if indicated   
Clinical Chemistry Assayed by [CONTACT_11007]-designated laboratory. 
Sodium   
Potassium   
Chloride   
Bicarbonate   
Total bilirubin   
Direct bilirubin   
Alkaline phosphatase (ALP)   
Alanine aminotransferase (ALT)   
Aspartate aminotransferase (AST)   
Gamma-glutamyl transferase (GGT)   
Blood urea nitrogen (BUN)   
Creatinine    
Creatine kinase (CK)   
Uric acid   
Total protein   
Albumin   
Calcium   
Phosphorus   
Glucose  
Lipid Panel Assayed by [CONTACT_11007]-designated laboratory.  
Total cholesterol  
Triglycerides  
High-density lipoprotein (HDL-C)  
Low-density lipoprotein (LDL-C) Generated by [CONTACT_11007]-designated laboratory. 
If triglycerides are >400, direct LDL will be measured. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
71 Very low-density lipoprotein (VLDL-C) Generated by [CONTACT_11007]-designated laboratory. 
Hormones (female)   
Serum pregnancy  Assayed by [CONTACT_11007]-designated laboratory.  
Urine pregnancy Assayed and evaluated locally.  
Follicle-stimulating hormone (FSH)  Assayed by [CONTACT_11007]-designated laboratory.  
Urine Chemistry Assayed by [CONTACT_11007]-designated laboratory. 
Albumin   
Creatinine   
Calculations Generated by [CONTACT_11007]-designated laboratory.  
eGFR (CKD-EPI) calculated using creatinine  
Urinary albumin/creatinine ratio (UACR)    
Additional Testing  Assayed by [CONTACT_11007]-designated laboratory.   
HbA1c   
Calcitonin  
10.2.1. Laboratory Samples to be Obtained at the Time of a Systemic Hypersensitivity 
Event 
Purpose of collecting samples afte r a systemic hypersensitivity event 
The samples listed in this appendix are not co llected for acute study participant management. 
The sponsor will use the laboratory test results from these samples to characterize 
hypersensitivity events across the clinical development program. 
When to collect samples after a syst emic hypersensitivity event occurs 
Collect the samples listed below if a systemic hypersensitivity event is suspected. The timing 
should be as designated in the table, assuming the participant has been stabilized. 
Obtain follow-up predose samples at the next regularly scheduled laboratory sample collection, 
ideally prior to the next dose after the event, to assess post-event return-to-baseline values. 
$SSURYHGRQ$XJ*[ADDRESS_355872] from 30 min to 4 h after the start of the 
event.  
P Note: The optimal collection time is from 1 
to 2 h after the start of event. Total tryptase 
Complements (C3, C3a, and C5a) 
Cytokine panel (IL- SQS
8;*7B,B=8427.9*7.5
that includes these 3 cytokines)  
Collect only if not already collected on the same 
day as the event.  
P Note: If collecting, collect up to 12 h after 
the start of the event. Tirzepatide anti-drug antibodies 
Tirzepatide concentration 
Abbreviation: IL = interleukin. 
a All samples for hypersensitivity testing will be assayed by [CONTACT_11007]-designated laboratory, if a validated assay is 
available. Results will not be provided to the study site.  If samples are not collected or are collected outside the 
specified time period, this will not be considered a protocol deviation. 
What information to record  
Record the date and time when the samples are collected. 
Allowed additional testing for participant management 
The investigator may perform additional tests locally, if clinically indicated, for acute study 
participant management. 
  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
73 10.3. Appendix 3: Adverse Events and Serious Adverse Events: Definitions 
and Procedures for Recording,  Evaluating, Follow-Up, and 
Reporting 
 The definitions and procedures detailed in this appendix are in accordance with 
ISO [ZIP_CODE]. 
 Both the investigator and the sponsor will comply with all local medical device reporting requirements. 
 The detection and documentation procedures described in this protocol apply to all sponsor medical devices provided for use in the study. See Section 6.1.[ADDRESS_355873] of 
sponsor medical devices. 
 Section 8.3.1 provides information on the timing and mechanism for collecting events. 
 Section 8.3.3 provides more information on the co llection and reporting of AEs and 
SAEs for the clinical endpoints. 
10.3.1. Definition of AE 
AE definition 
 An AE is any untoward medical occurr ence in a participant administered a 
pharmaceutical product and which does not nece ssarily have a causal relationship with 
the study intervention. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding ), symptom, or disease (new or exacerbated) 
temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. 
 An AE is any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory fi nding) in study participants, users, or 
other persons, whether or not related to the i nvestigational medical device. This definition 
includes events related to the investigati onal medical device or comparator and events 
related to the procedures involved except for events in users or other persons, which only include events related to investigational devices. 
Events meeting the AE definition 
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (for example, ECG, radiological scans, vital signs measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator, that is, not related to 
progression of underlying disease. 
 Exacerbation of a chronic or intermittent preexisting condition, including either an increase in frequency and/or intensity of the condition. 
 New condition detected or diagnosed after study intervention administration even though it may have been present before the start of the study. 
 Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
 Medication error, misuse, or abuse of IMP, including signs, symptoms, or clinical sequelae. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
74  Lack of efficacy or failure of expected pharmac ological action per se will not be reported 
as an AE or SAE. Such instances will be ca ptured in the efficacy assessments. However, 
the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be 
reported as AE or SAE if they fulfill the definition of an AE or SAE. 
Events NOT meeting the AE definition 
 Any clinically significant abnormal laboratory findings or other abnormal safety assessments that are associated with the underlying disease, unless judged by [CONTACT_941] 27?.<=20*=8;=8+.68;.<.?.;.= 1*7.A9.,=.-/8;=1.9*;=2,29*7 =L<,87-2=287  
 The disease/disorder being studied or expec ted progression, signs, or symptoms of the 
-2<.*<.	-2<8;-.;+.270<=>-2.->75.<<68;.<.?.;.=1*7.A9.,=. -/8;=1.9*;=2,29*7=L<
condition. 
 Medical or surgical procedure, for example, endoscopy and appendectomy: the condition that leads to the procedure is the AE. 
 Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospi[INVESTIGATOR_307]). 
 Anticipated day-to-day fluctuations of preexisting disease(s) or condition(s) present or detected at the start of the study that do not worsen. 
10.3.2. Definition of SAE 
An SAE is defined as any untoward medical occu rrence that, at any dose, meets 1 or more 
of the criteria listed: 
 Results in death 
 Is life-threatening 
o The term life-threatening  in the definition of serious  refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe. 
 Requires inpatient hospi[INVESTIGATOR_1081] 
o In general, hospi[INVESTIGATOR_291581] (usually involving at least an overnight stay) for 
observation and/or treatment that would not have been appropriate in the 91B<2,2*7L<8//2,.8;8>=9*=2.7=<.==270[ZIP_CODE],*=28 ns that occur during 
hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_1085], the event is serious. When in doubt as to whether hospi[INVESTIGATOR_51956], the AE should be considered serious. 
o Hospi[INVESTIGATOR_5187] a preexisting condition that did not 
worsen from baseline is not considered an AE. 
 Results in persistent disability/incapacity 
o &1.=.;6-2<*+252=B6.*7<*< >+<=*7=2*5-2<;>9=2878/*9.;<87L <*+252=B=8,87->,=
normal life functions. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
75 o This definition is not intended to include experiences of relatively minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma, for example, sprained ankle, which may interfere with or prevent everyday life functions but do not constitute a substantial disruption. 
 Is a congenital anomaly/birth defect 
o Abnormal pregnancy outcomes, for example, spontaneous abortion, fetal death, stillbirth, congenital anomalies, and ectopic pregnancy, are considered SAEs. 
 Other situations 
o Medical or scientific judgment should be exercised by [CONTACT_78278], such as important 
medical events that may not be immediately life-threatening or result in death or hospi[INVESTIGATOR_22772]. These events should usually be considered serious. 
o Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not resu lt in hospi[INVESTIGATOR_059], or development of 
drug dependency or drug abuse. 
 Resulted in medical or surgical intervention to  prevent life-threatening illness or injury or 
permanent impairment to a body structure or a body function. 
10.3.3. Definition of Product Complaints 
Product complaint 
 A product complaint is any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, dura bility, reliability, safety, effectiveness, or 
performance of a study intervention . When the ability to use the study intervention safely 
is impacted, the following are also Product Complaints: 
o deficiencies in labeling information, and 
o use errors for device or drug-device combination products due to ergonomic design elements of the product. 
 Product complaints related to study interventions used in clinical trials are collected to 
ensure the safety of participants, monitor qu ality, and to facili tate process and product 
improvements. 
 Investigators will instruct participants to con tact the site as soon as possible if he or she 
has a product complaint or problem with the study intervention so that the situation can 
be assessed. 
 An event may meet the definition of both a product complaint and an AE/SAE. In such cases, it should be reported as both a product complaint and as an AE/SAE. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
76 10.3.4. Recording and Follow-Up of AE and/or SAE and Product Complaints 
AE, SAE, and product complaint recording  
 When an AE/SAE/product complaint occurs, it is the responsibility of the investigator to 
review all documentation (for example, hos pi[INVESTIGATOR_1088], laboratory reports, and 
diagnostics reports) related to the event. 
 The investigator will then record all relevant AE/SAE/product complaint information in =1.9*;=2,29*7=L<6.-2,*5;.,8;-<27*,,8;-*7,. with =1.27?.<=20*=8;L<78;6*5,5272,*5
practice. AE/SAE information is reported on the appropriate CRF page and product 
complaint information is reported on the Product Complaint Form. Note: An event may meet the definition of both a product complaint and an AE/SAE. In such cases, it should be reported as both a product complaint and as an AE/SAE. 
 It is not *,,.9=*+5./8;=1.27?.<=20*=8;=8<.7-918=8,892.<8/=1.9*;= 2,29*7=L<6.-2,*5
records to sponsor or designee in lieu of co mpletion of the CRF page  for AE/SAE and the 
Product Complaint Form for product complaints. 
 There may be instances when copi[INVESTIGATOR_291582]. In this case, all partic ipant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_170249]. 
 The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs or symptoms) will be documented as the AE/SAE. 
Assessment of intensity 
The investigator will make an assessment of inte nsity for each AE and SAE reported during the 
study and assign it to 1 of the following categories: 
 Mild: A type of adverse event that is usually transient and may require only minimal 
treatment or therapeutic interve ntion. The event does not generally interfere with usual 
activities of daily living. 
 Moderate: A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with  usual activities of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research participant. 
 Severe: A type of adverse event that inter rupts usual activities of daily living, or 
significantly affects clinical status, or may require intensive therapeutic intervention. An 
AE that is assessed as severe should not be co nfused with an SAE. Severe is a category 
utilized for rating the intensity of an event; and both AEs and SAEs can be assessed as 
severe. 
An event is defined as JseriousK when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
77 Assessment of causality  
 The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE. The investigator will use clinical judgment to determine the relationship. 
 Jreasonable possibility K8/*;.5*=287<129,87?.B<=1*==1.;.*;. facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. 
 Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study intervention administration will be considered and investigated. 
 The investigator will also consult the IB in their assessment. 
 For each AE/SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality. 
 There may be situations in which an SAE has occurred and the investigator has minimal information to include in the initial report to sponsor or designee. However, it is very important that the investigator always make an assessment of causality for every event before the initial transmission of th e SAE data to sponsor or designee. 
 The investigator may change their opi[INVESTIGATOR_9242]-up information and send an SAE follow-up report with the updated causality assessment. 
 The causality assessment is one of the criteria used when determining regulatory reporting requirements. 
Follow-up of AEs and SAEs 
 The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by [CONTACT_291611]/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals. 
 If a participant dies during participation in the study or during a recognized follow-up period, the investigator will provide sponsor or designee with a copy of any postmortem findings including histopathology. 
10.3.5. Reporting of SAEs 
SAE reporting via an elec tronic data collection tool 
 The primary mechanism for reporting an SAE will be the electronic data collection tool. 
 If the electronic system is unavailable, then the site will use the SAE paper form (see next section) to report the event within 24 hours. 
 The site will enter the SAE data into the electronic system as soon as it becomes available. 
 After the study is completed at a given site , the electronic data collection tool will be 
taken off-line to prevent the entry of new data or changes to existing data. 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
78  If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the elect ronic data collection tool has been taken off-
line, then the site can report this information on an SAE paper form (see next section) or 
to the sponsor or designee by [CONTACT_756]. 
 Contacts for SAE reporting can be found in site training materials. 
SAE reporting via paper form 
 Facsimile transmission of the SAE paper form is the preferred method to transmit this 
information to the sponsor or designee. 
 Initial notification via telephone does not replace the need for the investigator to complete and sign the SAE CRF pages within the designated reporting time frames. 
 Contacts for SAE reporting can be found in site training materials. 
10.3.6. Regulatory Reporting Requirements 
SAE regulatory reporting 
Prompt notification by [CONTACT_11012] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of 
a study intervention under clinical investigation are met. 
 The sponsor has a legal responsibility to notify both the local regulatory authority 
and other regulatory agencies about the safety of a study intervention under 
clinical investigation. The sponsor will comply with country-specific regulatory 
requirements relating to safety reporting to the regulatory authority, IRB/IEC, and 
investigators. 
 An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (for example, summary or listing of SAEs) from the sponsor will review and then file it along with th e IB and will notify the IRB/IEC, if appropriate 
according to local requirements. 
  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
79 10.4. Appendix 4: Contraceptive and Barrier Guidance 
10.4.1. Definitions 
Word/Phrase Definition  
Women of 
childbearing 
potential (WOCBP)
 Adult females are considered WOCBP unless they are WNOCBP . 
Women not of 
childbearing 
potential  
(WNOCBP) Females are considered WNOCBP  if they 
 have a congenital anomaly such as MÃ¼llerian agenesis 
 are infertile due to surgical sterilization, or 
 are postmenopausal. 
Examples of surgical sterilization include total hysterectomy, bilateral 
salpi[INVESTIGATOR_8936] -oophorectomy, bilateral salpi[INVESTIGATOR_1656], or bilateral oophorectomy. 
Postmenopausal 
state The postmenopausal state is defined as  a woman: 
 at any age at least [ADDRESS_355874]- surgical bilateral oophorectomy 
with or without hysterectomy, confirmed by [CONTACT_31083]; or 
 aged at least [ADDRESS_355875] 
12 consecutive months without an alternative medical cause, AND 
with a follicle-stimulating hormone >40 mIU/mL; or 
 [ADDRESS_355876] 12 
months of spontaneous amenorrhea, or 
 aged at least 55 years with a diagnosis of menopause prior to 
starting hormone replacement therapy. 
a Women should not be taking medications during amenorrhea such as oral 
contraceptives, hormones, gonadotropin -releasing hormone, anti- estrogens, 
SERMs, or chemotherapy that could induce transient amenorrhea.  
Abbreviation: SERMs = selective estrogen receptor modulators. 
 
  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
80 10.4.2. Contraception Guidance 
[IP_ADDRESS]. Females  
Women of childbearing potential (WOCBP) and women not of childbearing potential 
(WNOCBP) may participate in this study. See Section 10.4.1 for definitions and additional 
requirements related to contraception. 
WOCBP who are completely abstinent as their preferred and usual lifestyle, or in a same-sex 
relationship as their preferred and usual lifestyle: 
    
agree to either 
remain abstinent or 
stay in a same -sex 
relationship without 
sexual relationships with males
  use periodic abstinence methods  
o calendar  
o ovulation  
o symptothermal, or  
o post-ovulation 
 declare abstinence just for the duration of the study, or 
 use the withdrawal method. 
 WOCBP who are NOT completely abstinent as their preferred and usual lifestyle, or NOT in a 
same-sex relationship as their preferred and usual lifestyle, must agree to do the following: 
Topic  Condition  
Pregnancy testing Have a negative serum test result at screening followed by a negative 
urine result within [ADDRESS_355877] dose of the study intervention.  
 
  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
81 Examples of different forms of contraception: 
Methods  Examples  
Highly effective 
contraception  (less than 
1% failure rate)   female sterilization 
 combination oral contraceptive pi[INVESTIGATOR_4382] 
 progestin-only contraceptive pi[INVESTIGATOR_4382] (mini-pi[INVESTIGATOR_4382]) 
 implanted contraceptives 
 injectable contraceptives 
 contraceptive patch (only women <198 pounds or 90 kg) 
 total abstinence 
 vasectomy (if only sexual partner) 
 fallopi[INVESTIGATOR_31077] (if confirmed by [CONTACT_31084][INVESTIGATOR_8913]) 
 combined contraceptive vaginal ring, or 
 intrauterine devices 
Effective contraception  male or female condoms with spermicide 
 diaphragms with spermicide or cervical sponges 
 barrier method with use of a spermicide 
o condom with spermicide, or 
o diaphragm with spermicide, or 
o female condom with spermicide. 
Ineffective forms  of 
contraception whether 
used alone or in any 
combination   spermicide alone 
 periodic abstinence 
 fertility awareness (calen dar method, temperature method, 
cervical mucus, or symptothermal) 
 withdrawal 
 postcoital douche, or 
 lactational amenorrhea 
  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
82 [IP_ADDRESS]. Men 
The table below describes contraception guidance for all men. 
Topic  Guidance  
For all men  should refrain from sperm donation for the 
duration of the study and for [ADDRESS_355878] injection 
Contraception for men with partners of 
childbearing potential   either remain abstinent, if this is their 
preferred and usual lifestyle 
or 
 must use condoms during intercourse 
for the duration of the study, and 
 for [ADDRESS_355879] injection 
Contraception for men in exclusively same-
sex relationships, as their preferred and usual lifestyle
 Are not required to use contraception  
Examples of highly effective, effective, and unacceptable methods of contraception can be found 
below. 
Methods  Examples  
Highly effective contraception   combination oral contraceptive pi[INVESTIGATOR_81061]-
pi[INVESTIGATOR_4382] 
 implanted contraceptives 
 injectable contraceptives 
 contraceptive patch (only women <198 
pounds or 90 kg) 
 total abstinence 
 vasectomy (if only sexual partner) 
 fallopi[INVESTIGATOR_31077] (if confirmed by 
[CONTACT_31084][INVESTIGATOR_8913]) 
 combined contraceptive vaginal ring, or 
 intrauterine devices 
Effective contraception   male or female condoms with spermicide 
 diaphragms with spermicide or cervical sponges 
 barrier method with use of a spermicide 
o condom with spermicide 
o diaphragm with spermicide, or 
o female condom with spermicide 
 
Note: The barrier method must include use of a 
spermicide (i.e., condom with spermicide, diaphragm 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
83 with spermicide, female condom with spermicide) to 
be considered effective.  
Ineffective forms of contraception   spermicide alone 
 immunocontraceptives 
 periodic abstinence 
 fertility awareness (calendar method, 
temperature method, combin ation of above 2, 
cervical mucus, symptothermal) 
 withdrawal 
 post coital douche, and 
 lactational amenorrhea 
  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
84 10.5. Appendix 5: Liver Safety: Suggested Actions and Follow-up 
Assessments  
Hepatic evaluation testing 
See protocol Section 8.2.[ADDRESS_355880] be qualified in accordance with applicable local regulations. 
Tests assayed by [CONTACT_11007] -designated central laboratory 
Hepatic Hematology Panel Hepatitis A virus (HAV) testing 
   Hemoglobin     HAV total antibody 
   Hematocrit     HAV IgM antibody 
   Erythrocytes (RBCs - red blood cells) Hepatitis B virus (HBV) testing  
   Leukocytes (WBCs - white blood cells)     Hepatitis B surface antigen (HBsAg) 
   Differential:     Hepatitis B surface antibody (anti-HBs) 
       Neutrophils, segmented     Hepatitis B core total antibody (anti-HBc) 
       Lymphocytes     Hepatitis B core IgM antibody 
       Monocytes     HBV DNA b 
       Basophils Hepatitis C virus (HCV) testing  
       Eosinophils     HCV antibody 
   Platelets     HCV RNA b 
   Cell morphology (RBC and WBC) Hepatitis D virus (HDV) testing  
Hepatic Clinical Chemistry Panel     HDV antibody  
   Total bilirubin Hepatitis E virus (HEV) testing  
   Direct bilirubin     HEV IgG antibody 
   Alkaline phosphatase (ALP)      HEV IgM antibody  
   Alanine aminotransferase (ALT)     HEV RNA b 
   Aspartate aminotransferase (AST) Anti-nuclear antibody (ANA) 
   Gamma-glutamyl transferase (GGT) Anti-smooth muscle antibody (ASMA) a 
   Creatine kinase (CK) Anti-actin antibody c 
Hepatic Coagulation Panel Immunoglobulin IgA (quantitative) 
   Prothrombin time, INR (PT-INR) Immunoglobulin IgG (quantitative) 
Urine Chemistry Immunoglobulin IgM (quantitative) 
   Drug screen Epstein-Barr virus (EBV) testing  
Haptoglobin     EBV antibody 
 
Tests assayed ONLY by [CONTACT_1697] -designated local laboratory  
Acetaminophen Cytomegalovirus (CMV) testing 
Acetaminophen protein adducts     CMV antibody 
Alkaline phosphatase isoenzymes     CMV DNA b 
Ceruloplasmin Herpes simplex virus (HSV) testing 
Copper     HSV (Type 1 and 2) antibody 
Ethyl alcohol (EtOH)     HSV (Type 1 and 2) DNA b 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
85 Phosphatidylethanol (PEth) Liver kidney microsomal type 1 (LKM-1) antibody  
Urine Chemistry  Microbiology  
    Ethyl glucuronide (EtG) Culture:  
Epstein-Barr virus (EBV) testing      Blood 
    EBV DNA b     Urine 
a Not required if anti-act in antibody is tested. 
b Reflex/confirmation dependent on regulatory requirements, testing availability, or both. 
c Not required if anti-smooth muscle antibody (ASMA) is tested.  
  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
86 10.6. Appendix 6: Medical Device Adverse Events (AEs), Adverse Device 
Effects (ADEs), Serious Adverse Events (SAEs) and Device Deficiencies: Definition and Procedures for Recording, Evaluating, Follow-up, and Reporting 
Refer to Section 10.3, Appendix 3 for definitions and procedures for recording, evaluating, 
follow-up, and reporting of all events. 
  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
87 10.7. Appendix 7: Standardized Protocols for the Measurement of Height, 
Weight, Waist Circumference, BMI, and Vital Signs 
The following information has been adapted from standardized physical measurement protocols 
/8;=1.)8;5-.*5=1";0*72C*=287L<  STEP wise approach to Surveillance Manual. 
Measuring height 
Step 1.   Ask the participant to remove their footwear and any headgear; light headgear worn for 
religious reasons can remain, but this should be worn by [CONTACT_291612]. 
Step 2.   Ask the participant to stand on the calibra ted height measuring board (stadiometer) or 
against a wall with their feet together and their knees straight with their heels against the 
backboard, the stadiometer, or the wall. 
Step 3.   Ask the participant to look straight ahead without tilting their head up. 
Step 4.   Ask the participant to breathe in and stand tall. If using a stadiometer or fixed measuring 
device, move the -.?2,.L<6.*<>;.6.7=*;60.7=5B-8@787=8=1.=898/=1.9*;=2, 29*7=L<1.*-
$.,8;-=1.9*;=2,29*7=L<1.201= 27,.7=26.=.;,6=8-.,26*595*,.  
Measuring weight  Body weight measurements should be done in a consistent manner using a calibrated 
electronic scale capable of measuring weight in kilogram. 
 All weights for a given participant should be measured using the same scale, whenever possible. 
 Participants should be lightly clothed but not wearing shoes while their weight is measured. 
 Step 1 .  Ask the participant to remove their foot wear, outerwear (coat, jacket, etc.), and any 
headgear; light headgear worn for religious reasons can remain, but this should be worn by [CONTACT_291613]. 
Step 2 .  Make sure the scale is placed on a firm, flat, even surface (not on carpet, on a slopi[INVESTIGATOR_126154], or a rough, uneven surface). Step [ADDRESS_355881] weight in kilogram 
(kg) to the nearest one-tenth kg. 
Measuring waist circumference 
 Use non-stretchy tape 
 Waist circumference should be measured at midpoint, between lower margin of last palpable 
rib and top of iliac crest (approximately 1 inch [2.54 cm] above the navel) 
 Participants should be lightly clothed, and 
 Measure to the nearest 0.5 cm.  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
88 Step 1.  Ask the participant to stand with their feet close together, and arms at their side with their 
body weight evenly distributed. 
Step 2.  Ask participant to relax. 
Step 3.  Measurements should be recorded at the end of a normal expi[INVESTIGATOR_1516]. 
Calculation of BMI 
Height and weight measurements will be used to calculate BMI. 
 BMI = weight (kg) / [height (m)]2. 
Calculation of BMI with amputation or limb loss 
In participants with limb amputation or limb loss, use the formula given in the following link: 
Amputee Coalition H https://www.amputee-coalition.org/li mb-loss-resource-center/resources-
filtered/resources-by-topic/healthy-living/about-bmi/. 
Vital sign measurements (blood pressure and heart rate)  
 Vital sign measurements, measured by [CONTACT_117682], should be taken before obtaining an ECG 
tracing and before collection of blood samples for laboratory testing. 
 An appropriately sized cuff (cuff bladder encircling at least 80% of the arm) should be 
used to ensure the accuracy of BP measurements. 
 Blood pressure should be taken with an  automated blood pressure instrument. 
 If blood pressure and pulse measurements are taken separately, pulse should be taken 
prior to blood pressure. 
Step 1.  The participant should sit quietly for approximately [ADDRESS_355882] 1 minute apart. Each measurement of sitting 
pulse and blood pressure needs to be recorded in the CRF. 
Note: In the event pulse measurement cannot be taken via an automated blood pressure 
instrument, the preferred location for measurement of pulse is the radial artery. 
  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
89 10.8. Appendix 8: Provisions for Changes in Study Conduct During 
Exceptional Circumstances 
Implementation of this appendix 
The changes to procedures described in this appendix are temporary measures intended to be 
used only during specific time periods as directed by [CONTACT_52019]. 
Exceptional circumstances 
Exceptional circumstances are rare events that may cause disruptions to the conduct of the study. 
Examples include pandemics or natural disasters.  These disruptions may limit the ability of the 
investigators, participants, or both to attend on-site visits or to conduct planned study procedures. 
Implementing changes und er exceptional circumstances 
7*7.A,.9=287*5,2;,>6<=*7,.*/=.;;.,.2?270=1.<987<8;L<@;2==.7*99;8?*5<2=.<6*B
implement changes if permitted by [CONTACT_427]. 
After approval by [CONTACT_31086], regulatory bodies, and any other relevant local 
authorities, implementation of these exceptional ci rcumstance changes will not typi[INVESTIGATOR_51960], unless they have specific requirements in which 
notification is required, for example, upon implementation and suspension of changes. All approvals and notifications must be retained in the study records.  
If the sponsor grants written approval for change s in study conduct, the sponsor will also provide 
additional written guidance, if needed. 
Considerations for making a change 
The prevailing consideration for making a change is ensuring the safety of study participants. 
Additional important considerations for making a change are compliance with Good Clinical Practice, enabling participants to continue safely in the study and maintaining the integrity of the study. 
Informed consent 
Additional consent from the participant will be obtained, if required, for: 
 participation in remote visits, as defined in Section J$.68=.(2<2=<K  
 a change in the method of study intervention administration 
 dispensation of additional study intervent ion during an extended treatment period 
 alternate delivery of study intervention and ancillary supplies, and 
 provision of their personal or medical information required prior to implementation of 
these activities. 
Changes in study conduct during exceptional circumstances 
Changes in study conduct not described in this appendix, or not consistent with applicable local 
regulations, are not allowed. 
$SSURYHGRQ$XJ*[ADDRESS_355883] will not be considered protocol deviations. 
Remote visits 
Types of remote visits: 
Telemedicine:  
Telephone or technology-assis ted virtual visits, or both, are acceptable to complete 
appropriate assessments. The study site shoul d capture the visit location and method with 
a specific explanation for any data missing because of missed in-person site visits in 
source document and CRF. Examples of assessments to be completed in this manner include AEs and PCs, concomitant medications, review study participant diary, including 
study intervention compliance, review diet, and exercise goals. 
Mobile healthcare:  
Healthcare visits may be performed by a mobile healthcare provider  at locations other 
than the study site when participants cannot travel to the site due to an exceptional 
circumstance if written approval is provided by [CONTACT_291614]. Procedures performed at such visits may include, but are not limited to, weight measurement, blood sampling, vital signs, conducting physical assessments, and collecting health information. Every effort should be made for the particip ant to return to on-site visits as soon as 
reasonably possible, while ensuring the safety  of the participant and investigational site 
staff. 
Additional consent from the participant will be obtained for participants if needed per 
local regulations. 
Data capture 
In source documents and the CRF, the study site  should capture the visit method, with a specific 
explanation for any data missing because of missed in-person site visits. 
Safety reporting 
Regardless of the type of remote visits imple mented, the protocol requirements regarding the 
reporting of AEs, SAEs, and PCs remain unchanged. 
Return to on-site visits 
Every effort should be made to enable participants to return to on-site visits as soon as 
reasonably possible, while ensuring the safety of both the participants and the site staff. 
Local laboratory testing option 
Local laboratory testing may be conducted in lieu of central laboratory testing. However, central 
laboratory testing must be retained for calcitonin. The local laboratory must be qualified in 
accordance with applicable local regulations.  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
91 Study intervention and ancillary supplies (including participant diaries) 
When a participant is unable to go to the site to receive study supplies during normal on-site 
visits, the site should work with the sponsor to determine appropriate actions. These actions may include 
 asking the participant to go to the site and receive study supplies from site staff 
without completion of a full study visit 
 *<4270=1.9*;=2,29*7=L<-.<207..=808=8=1.<2=.*7-;.,.2?. <=>-B supplies on a 
9*;=2,29*7=L<+.1*5/*7-  
 arranging delivery of study supplies. 
These requirements must be met before action is taken: 
 Alternate delivery of study intervention s hould be performed in a manner that does 
not compromise treatment blinding and ensures product integrity. The existing 
protocol requirements for product accountability remain  unchanged, including 
?.;2/2,*=2878/9*;=2,29*7=L<;.,.29=8/<=>-B<>9952.<  
 When delivering supplies to a location ot her than the study site (for example, 
parti,29*7=L<186.=1.27?.<=20*=8;<987<8;8;+8=[ADDRESS_355884] packaging upon receipt. 
 Instructions may be provided to the participant or designee on the final disposition of 
any unused or completed study supplies. 
If study intervention will be administered to the participant during a mobile healthcare visit 
or at an alternate location, this additional requirement must be met: 
 Only authorized study personnel may supply, prepare, or administer study 
intervention. 
Screening period guidance  
Visit [ADDRESS_355885] be paused due to exceptional circumstances: 
 If screening is paused for less than 30 days from screening to Visit 2: the participant 
will proceed to the next study visit per the usual SoA, provided that Visit [ADDRESS_355886] screening. 
o &1.<2=.<18>5-,87->,==1.7.A=?2<2=2/=1.9*;=2,29*7=L<.52 02+252=B,;2=.;2**;.
confirmed, and the site should document the reason for delay. 
o Due to the pause in screening, sites should also reconfirm the impacted 
9*;=2,29*7=L<,87<.7=*7--8,> 6.7==12<,87/2;6*=28727=1.<8> ;,.
documentation. 
 If screening is paused for more than 30 days from screening: The participant must be 
discontinued because of screening interruption due to an exceptional 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
92 circumstance. This is documented as a screen failure in the CRF. The participant can 
reconsent and be rescreened as a new particip ant. This rescreen is in addition to the 
one allowed by [CONTACT_141730]. The screening procedures per the usual SoA should be followed, starting at the screening visit to ensure participant eligibility by [CONTACT_4838] 2. 
Adjustments to visit windows 
Whenever possible and safe to do so, as determined by [CONTACT_227669] =20*=8;L<-2<,;.=2879*;=2,29*7=<
should complete the usual SoA. To maximize the possibility that these visits can be conducted as 
on-site visits, the windows for visits may be ad justed, upon further guidance from the sponsor. 
This minimizes missing data and preserves the intended conduct of the study. 
For participants whose visits have extended windows, additional study intervention may need to 
be provided to avoid interruption and maintain overall integrity of the study. 
The primary endpoint visit and end of treatment visit, Visit 5 (Week 12), should be completed 
per original schedule whenever possible and safe to do so. The visit window should be within Â±[ADDRESS_355887] will be documented 
Sites will identify and document the details of how participants, visits types, and conducted 
activities were affected by [CONTACT_291615]. Dispensing/shipment records of study 
intervention and relevant communications, including delegation, should be filed with site study 
records. 
Source documents at alternate locations 
Source documents generated at a location other than the study site should be part of the 
27?.<=20*=8;L<  source documentation and should be transferred to the site in a secure and timely 
manner.  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
93 10.9. Appendix 9: Abbreviations and Definitions 
Term Definition 
abuse  use of a study intervention for recreational purposes or to maintain an addiction or 
dependence  
ADA  American Diabetes Association  
AE adverse event 
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
Anti -GAD anti-glutamic acid decarboxylase 
AST  aspartate aminotransferase  
BG blood  glucose 
BMI  body mass index  
CFR  Code of Federal Regulations  
CGM  continuous glucose monitoring  
CIOMS  Council for International Organizations of Medical Sciences  
CK creatine kinase  
CKD -EPI [INVESTIGATOR_291583] - epi[INVESTIGATOR_291584]  A complaint is any written, electronic, or oral communication that alleges deficiencies related 
to the identity, quality, purity, durability, reliability, safety or effectiveness, or performance of a drug or drug delivery system
 
compliance  Adherence to all study -related, good clinical practice (GCP ), and applicable regulatory 
requirements  
CONSORT Consolidated Standards of Reporting Trials  
CRF  case report form; a printed, optical, or electron ic document designed to record all of the 
protocol -required information to be reported to  the sponsor for each trial participant 
CT computed tomography  
CV cardiovascular 
CVD  cardiovascular disease 
Device 
deficiencies equivalent to product complaint 
$SSURYHGRQ$XJ*[ADDRESS_355888] been assigned to a treatment  
enter  participants entered into a study are those who sign the informed consent form directly or 
through their legall y acceptable representatives 
FBG  fasting blood glucose  
FSG  fasting serum glucose  
GCP  good clinical practice  
GGT  gamma -glutamyl transferase 
GI gastrointestinal 
GIP glucose -dependent insulinotropic polypeptide  
GLP -1 05>,*087S524.9.9=2-.S  
GLP -[ADDRESS_355889] 
HbA1c  hemoglobin A1c  
IB 7?.<=20*=8;L<;8,1>;.  
ICF informed consent form  
ICH  International Council for Harmonisation  
IMP  7?.<=20*=287*5 .-2,27*5#;8->,=<..*5<8J investigational product K 
A medicinal product which is being tested or used  as a reference, including as a placebo, in a 
clinical trial.  
informed 
consent  a process by [CONTACT_9444] a participan t voluntarily confirms their willingness to participate in a 
particular study, after having been informed of  all aspects of the study that are relevant to the 
9*;=2,29*7=L<-.,2<287=89*;=2,29*=.7/8;6.-,87<.7=2<-8,>6.7=.-+B6.*7<8/*@;2==.7
signed, and dated informed consent form . 
interim 
analysis  an interim analysis is an analysis of clinical study data, separated into trea tment groups, that is 
conducted before the final reporting database is created  or locked 
$SSURYHGRQ$XJ*[ADDRESS_355890]  a pharmaceutical form of an active ingredient or placebo being tested or used as a reference in 
a clinical trial, including products already on the market when used or assembled (formulated 
or packaged) in a way different from the auth orized form, or marketed products used for an 
unauthorized indication, or marketed products used to gain further information about the *>=18;2C.-/8;6%..*5<8J #K
 
IRB/IEC  Institutional Review Board/Independent Ethics Committee  
ISR injection -site reaction 
ITT intention to  treat: The principle that asserts that the ef fect of a treatment policy can be best 
assessed by [CONTACT_291616] a participan t (that is, the planned 
treatment -regimen) rather than the actual treatment given. It has the consequence that 
participant allocated to a treatm ent group should be followed up, assessed, and analyzed as 
members of that group irrespective of their co mpliance to the planned course of treatment 
IWRS  interactive web -response system 
IW-SP Impact of Weigh t on Self Perception 
LADA  latent autoimmune diabetes in adults  
medication 
error  errors in the prescribing, dispensing, or admi nistration of a study intervention, regardless of 
whether or not the medication is administered to  the participant or the error leads to an AE. 
Medication error generally involve s */*25>;.=8>9185-8;68;.8/=1.J;201=<K8/
medication use: the right participant, the right drug, the right dose, right route, at the right 
time.  
In addition to the core 5 rights, the following ma y also represent medication errors:  
D-8<.862<<287*<<8,2*=.-@2=1*78;*9;8->,=,8695*27=  
D-2<9.7<2708;><.8/.A92;.-6.-2,*=287  
D><.8/6.-2,*=2879*<==1.;.,866.7-.-27 -use date 
D-2<9.7<2708;><.8/*7269;89.;5B<=8;.-6.-2,*=287  
D><.8/  an adulterated dosage form or administration technique inconsistent with the 
6.-2,*=287L<5*+.[ADDRESS_355891] Characteristics, IB , local label, 
protocol, or 
D<1*;.-><.8/,*;=;2-0.<9;. -filled pens, or both. 
misuse  use of a study intervention for self- treatment that either is inconsistent with the prescribed 
dosing regimen, indication, or both, or is obtained without a prescription  
MEN2  multiple endocrine neoplasia syndrome type 2  
mITT  modified intent -to-treat 
MMRM  mixed model for repeated measures 
MRI  magnetic resonance imaging  
MTC  medullary thyroid carcinoma  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
96 MTD  maximum tolerated dose  
NAFLD  nonalcoholic fatty liver disease  
OAM  oral antihyperglycemic medication  
participant  e:>2?*5.7==8%=.;6J<>+3.,=K*727-2?2->*[ADDRESS_355892] complaint  
PK/PD  pharmacokinetics/pharmacodynamics  
QTc  corrected QT interval  
QD once -daily 
QW once -weekly 
RA receptor agonist  
SAE  serious adverse event  
SAP  statistical analysis plan  
SC subcutaneous  
screen  the act of determining if an individual meets mi nimum requirements to become part of a pool 
of potential candidates for par ticipation in a clinical study  
SDP  single -dose pen 
SGLT -2i sodium -glucose cotransporter-2 inhibitor 
SMBG  self-monitoring of blood glucose 
SoA schedule of activities  
T1D  Type-1 diabetes 
T2D  Type-2 diabetes 
TBL  total bilirubin  
TEAE  treatment -emergent adverse event: An untoward medical occurrence that emerges during a 
defined treatment period, having been absent  pretreatment, or worsens relative to the 
pretreatment state, and does not necessarily have  to have a causal relationship with this 
treatment  
ULN  upper limit of normal  
WOCBP  woman of child bearing potential 
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
97 WNOCBP  women not of childbearing potential  
  
$SSURYHGRQ$XJ*07
CONFIDENTIAL I8F-MC-GPIL 
98 11. References 
[ADA] American Diabetes Association. Introduction:  Standards of Medical Care in Diabetes I
2022. Diabetes Care . 2022;45(Suppl 1): S1-S2. https://doi.org/10.2337/dc22-Sint 
Almandoz JP, Lingvay I, Morales J, Campos C. Switching between glucagon-like peptide-1 
receptor agonists: rationale and practical guidance. Clin Diabetes. 2020;38(4): 390-402. 
https://doi.org/10.2337/cd19-0100 
Banks PA, Freeman ML; Practice Parameters Committee of the American College of 
Gastroenterology. Practice guidelines in acute pancreatitis. Am J Gastroenterol . 
2006;101(10):2379-2400. https://doi.org/10.1111/j.1572-0241.2006.[ZIP_CODE].x 
Battelino T, Bergenstal R, Rodriguez A. et al. Effect of tirzepatide versus insulin degludec on 
glycaemic control captured with continuous glucose monitoring in patients with type 2 
diabetes (SURPASS-3 CGM). In Diabetologia  (Vol. 64, No. Suppl 1, pp. 244-244); 2022. 
[LOCATION_001], NY, [LOCATION_002]: Springer 
Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of hyperglycemia in type 2 
diabetes, 2018. A Consensus Report by [CONTACT_11026] (ADA) and the 
European Association for the Study of Diabetes (EASD). Diabetes Care . 2020;43(2):487-493. 
https://doi.org/ 10.2337/dci19-0066. Erratum in: Diabetes Care . 2020;43(7):1670. 
https://doi.org/10.2337/dc20-er07  
Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to 
titrated insulin  glargine on glycemic control in patients with type 2 diabetes: The SURPASS-5 
randomized clinical trial. JAMA. 2022;327(6):534-545. 
https://doi.org/10.1001/jama.2022.0078  
Danne T, Philotheou A, Goldman D, et al. A randomized trial comparing the rate of 
hypoglycemia H assessed using continuous glucose monitoring H in 125 preschool children 
with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study). 
Pediatr Diabetes . 2013;14(8):593-601. https://doi.org/ 10.1111/pedi.[ZIP_CODE] 
Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide ve rsus insulin glargine in type 2 diabetes and 
increased cardiovascular risk (SURPASS- 4): a randomised, open-label, parallel-group, 
multicentre, phase 3 trial. Lancet . 2021;398([ZIP_CODE]):1811-1824. https://doi.org/10.1016/S0140-
6736(21)[ZIP_CODE]-7 
FrÃ­as JP, Davies MJ, Rosenstock J, et al. Tirzepa tide versus semaglutide once weekly in patients 
with type 2 diabetes. N Engl J Med . 2021;385(6):503-515 . 
https://doi.org/10.1056/NEJMoa2107519 
FrÃ­as JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-
[ADDRESS_355893], in patients with type 2 diabetes: a randomised, placebo-controlled and 
active comparator-controlled phase 2 trial. Lancet . 2018;392([ZIP_CODE]):2180-2193. 
https://doi.org/10.1016/S0140-6736(18)[ZIP_CODE]-[ADDRESS_355894] . 2020;26(1):107-139. https://doi.org/10.4158/CS-2019-0472 
$SSURYHGRQ$XJ*[ADDRESS_355895] of tirzepatide versus insulin degludec on liver fat 
content and abdominal adipose tissue in patients  with type 2 diabetes (SURPASS-3 MRI). In 
Diabetologia  (Vol. 64, No. Suppl 1, pp. 219-220); 2022. [LOCATION_001], NY, [LOCATION_002]: 
Springer 
Hepprich M, Zillig D, Florian-Reynoso MA, et al. Switch-to-semaglutide study (STS-Study): a 
retrospective cohort study. Diabetes Ther . 2021;12(3):943-954. 
https://doi.org/10.1007/s13300-021-[ZIP_CODE]-y 
Jain AB, Ali A, Gorgojo MartÃ­nez JJ, et al. Switching between GLP-1 receptor agonists in 
clinical practice: Expert consensus and practical guidance. Int J Clin Pract . 
2021a;75(2):e13731. https://doi.org/ 10.1111/ijcp.[ZIP_CODE] 
Jain AB, Kanters S, Khurana R, et al. Real -world effectiveness analysis of switching from 
liraglutide or dulaglutide to semaglutide in patients with type 2 diabetes mellitus: the 
retrospective REALISE-DM study. Diabetes Ther . 2021b;12(2):527-536. 
https://doi.org/10.1007/s13300-020-[ZIP_CODE]-x 
Koizumi M, Takada T, Kawarada Y, et al.  JPN guidelines for the management of acute 
pancreatitis: diagnostic criteria for acute pancreatitis. J Hepatobiliary Pancreat Surg . 
2006;13(1):25-32. https://doi.org/10.1007/s00534-005-1048-2 
Ludvik B, Giorgino F, JÃ³dar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec 
as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes 
(SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet . 
2021;398([ZIP_CODE]):583-598. https://doi.org/ 10.1016/S0140-6736(21)[ZIP_CODE]-4  
Mounjaro [package insert]. Indianapolis, IN, [LOCATION_003]: Eli Lilly and Company; 2022. 
Neumiller JJ. Clinical pharmacology of incretin therapi[INVESTIGATOR_36259] 2 diabetes mellitus: 
implications for treatment. Clin Ther . 2011;33(5):528-576. 
https://doi.org/ 10.1016/j.clinthera.2011.04.[ADDRESS_355896] tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, 
randomised, phase 3 trial. Lancet . 2021;398([ZIP_CODE]):143-155. https://doi.org/10.1016/S0140-
6736(21)[ZIP_CODE]-6. Erratum in: Lancet . 2021;398([ZIP_CODE]):212. https://doi.org/10.1016/S0140-
6736(21)[ZIP_CODE]-7 
Weinberg ME, Bacchetti P, Rushakoff RJ. Frequently repeated glucose measurements 
overestimate the incidence of inpatient hypoglycemia and severe hyperglycemia. J Diabetes 
Sci Technol . 2010;4(3):577-582. https://doi.org/10.1177/193229681000400311 
$SSURYHGRQ$XJ*07
6LJQDWXUH3DJHIRU99&/,1Y
6LJQDWXUH3DJHIRU99&/,1Y$SSURYDO
$XJ*07
$SSURYDO
$XJ*07
$SSURYHGRQ$XJ*07[COMPANY_003]
[COMPANY_003]